

# Supporting Information

## Divergent Synthesis of Silicon-Containing Peptides via Pd-Catalyzed Post-Assembly $\gamma$ -C(sp<sup>3</sup>)-H Silylation

Bei-Bei Zhan, Jun Fan, Liang Jin, Bing-Feng Shi\*

Department of Chemistry, Zhejiang University, Hangzhou, 310027, China

\*Email: bfshi@zju.edu.cn

### Table of Contents

1. General Information.....	S2
2. Synthesis and Characterization of Starting Materials.....	S2
3. Optimization of Reaction Conditions.....	S10
4. General Procedure for $\gamma$ -C(sp <sup>3</sup> )-H Silylation.....	S13
5. Applications of the Silylation Reaction.....	S31
6. Crystal Structure of <b>4o</b> .....	S32
7. References.....	S33
8. NMR Spectra .....	S34
9. Copies of HPLC Analysis.....	S115

## 1. General Information

Nuclear magnetic resonance (NMR) spectra were recorded with Bruker AVANCE 400MHz.  $^1\text{H}$  and  $^{13}\text{C}$  chemical shifts are reported in ppm downfield of tetramethylsilane and referenced to residual solvent peak as following:  $\text{CHCl}_3 = 7.26$  ( $^1\text{H}$  NMR),  $(\text{CH}_3)_2\text{SO} = 2.50$  ( $^1\text{H}$  NMR), toluene = 2.08, 6.97, 7.01, 7.09 ( $^1\text{H}$  NMR),  $\text{CDCl}_3 = 77.16$  ( $^{13}\text{C}$  NMR),  $(\text{CD}_3)_2\text{SO} = 40.00$  ( $^{13}\text{C}$  NMR). Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dddd = doublet of doublet of doublet of doublets, t = triplet, q = quartet, m = multiplet. High-resolution mass spectra (HRMS) for new compounds were recorded on ESI-TOF. Unless otherwise noted, all commercial materials were purchased from Adamas, Aladdin and Energy Chemicals and used without further purification.  $\text{Pd}(\text{OAc})_2$  was obtained from Stream®.


## 2. Synthesis and Characterization of Starting Materials

### 2-1. Synthesis of Starting Materials

The preparation of substrates **1a-1m**, **1q**, **1r**, **3o** and **5e-5h** have been reported.<sup>1-9</sup>


#### General Procedure (GP-1) for the synthesis of peptides.

##### A) Synthesis of dipeptides **3a-3n**.




A mixture of Boc-*L*-valine (1.0 eq), amino acid methyl esters (1.1 eq), EDCI (1.1 eq), HOBT (1.1 eq), and DIPEA (3.0 eq) in DCM was stirred at  $-10\text{ }^\circ\text{C}$  for 2 hours, then warmed to room temperature for overnight. Water was added and the mixture was extracted with DCM. The combined organic layers was washed with water and brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated in vacuo. The mixture dissolved in DCM was treated with trifluoroacetic acid for 4 hours and then concentrated in vacuo. The crude oil was finally mixed with picolinic acid (1.1 eq), EDCI (1.1 eq), HOBT (1.1 eq), and DIPEA (3.0 eq) in DCM and stirred at  $-10\text{ }^\circ\text{C}$  for 2 hours, then warmed to room temperature for overnight. Water was added and the mixture was extracted with DCM. The combined organic layers was washed with water and brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated in vacuo. The resulting residue was purified by flash chromatography to give the corresponding dipeptides.

**B) Synthesis of tripeptides 5a-5d.**



A mixture of Boc-*L*-amino acid (1.0 eq), amino acid methyl esters (1.1 eq), EDCI (1.1 eq), HOBT (1.1 eq), and DIPEA (3.0 eq) in DCM was stirred at  $-10\text{ }^\circ\text{C}$  for 2 hours, then warmed to room temperature for overnight. Water was added and the mixture was extracted with DCM. The combined organic layers was washed with water and brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated in vacuo. The mixture dissolved in DCM was treated with trifluoroacetic acid for 4 hours and then concentrated in vacuo, repeat the operation again. The crude oil was finally mixed with picolinic acid (1.1 eq), EDCI (1.1 eq), HOBT (1.1 eq), and DIPEA (3.0 eq) in DCM and stirred at  $-10\text{ }^\circ\text{C}$  for 2 hours, then warmed to room temperature for overnight. Water was added and the mixture was extracted with DCM. The combined organic layers was washed with water and brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated in vacuo. The resulting residue was purified by flash chromatography to give the corresponding tripeptides.

**C) Synthesis of tetrapeptides 5i-5j.**




A mixture of Boc-*L*-amino acid (1.0 eq), amino acid methyl esters (1.1 eq), EDCI (1.1 eq), HOBT (1.1 eq), and DIPEA (3.0 eq) in DCM was stirred at  $-10\text{ }^{\circ}\text{C}$  for 2 hours, then warmed to room temperature for overnight. Water was added and the mixture was extracted with DCM. The combined organic layers was washed with water and brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated in vacuo. The mixture dissolved in DCM was treated with trifluoroacetic acid for 4 hours and then concentrated in vacuo, repeat the operation for twice. The crude oil was finally mixed with picolinic acid (1.1 eq), EDCI (1.1 eq), HOBT (1.1 eq), and DIPEA (3.0 eq) in DCM and stirred at  $-10\text{ }^{\circ}\text{C}$  for 2 hours, then warmed to room temperature for overnight. Water was added and the mixture was extracted with DCM. The combined organic layers was washed with water and brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated in vacuo. The resulting residue was purified by flash chromatography to give the corresponding tetrapeptides.




## 2-2. Characterization of Starting Materials

### (S)-Methyl 3-methyl-2-((S)-3-methyl-2-(picolinamido)butanamido)butanoate (3a)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.66 – 8.49 (m, 2H), 8.19 (d, *J* = 7.6 Hz, 1H), 7.84 (td, *J* = 8.0, 1.6 Hz, 1H), 7.46 – 7.41 (m, 1H), 6.69 (d, *J* = 8.4 Hz, 1H), 4.57 – 4.49 (m, 2H), 3.73 (s, 3H), 2.36 – 2.26 (m, 1H), 2.22 – 2.10 (m, 1H), 1.03 (dd, *J* = 6.8, 3.2 Hz, 6H), 0.93 – 0.85 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.37, 171.19, 164.66, 149.49, 148.46, 137.46, 126.51, 122.46, 58.94, 57.32, 52.27, 31.22, 31.10, 19.53, 19.04, 18.31, 17.93. HRMS (ESI): calcd. for C<sub>17</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 358.1737, found: 358.1721

### (S)-Methyl 3,3-dimethyl-2-((S)-3-methyl-2-(picolinamido)butanamido)butanoate (3b)



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.70 – 8.45 (m, 2H), 8.21 (d, *J* = 7.2 Hz, 1H), 7.85 (t, *J* = 6.8 Hz, 1H), 7.52 – 7.30 (m, 1H), 6.89 – 6.65 (m, 1H), 4.79 – 4.31 (m, 2H), 3.72 (s, 3H), 2.40 – 2.20 (m, 1H), 1.18 – 0.75 (m, 15H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.92, 171.00, 164.66, 149.45, 148.44, 137.45, 126.51, 122.48, 60.27, 58.89, 51.92, 34.71, 30.96, 26.68, 19.54, 18.35. HRMS (ESI): calcd. for C<sub>18</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 372.1893, found: 372.1893.


### (2S,3S)-Methyl 3-methyl-2-((S)-3-methyl-2-(picolinamido)butanamido)pentanoate (3c)



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.63 – 8.49 (m, 2H), 8.19 (d, *J* = 7.8 Hz, 1H), 7.83 (td, *J* = 7.6, 1.6 Hz, 1H), 7.44 – 7.39 (m, 1H), 6.78 (d, *J* = 8.4 Hz, 1H), 4.61 – 4.51 (m, 2H), 3.72 (s, 3H), 2.35 – 2.25 (m, 1H), 1.93 – 1.81 (m, 1H), 1.42 – 1.35 (m, 1H), 1.18 – 1.09 (m, 1H), 1.02 (dd, *J* = 6.8, 4.8 Hz, 6H), 0.89 – 0.78 (m, 7H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.33, 171.07, 164.61, 149.54, 148.44, 137.41, 126.46, 122.45, 58.82, 56.62, 52.16, 37.83, 31.24, 25.32, 19.47, 18.30, 15.54, 11.63. HRMS (ESI): calcd. for C<sub>18</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>:


372.1893, found: 372.1879.

### (S)-Methyl 1-((S)-3-methyl-2-(picolinamido)butanoyl)pyrrolidine-2-carboxylate (3d)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.62 (d, *J* = 9.2 Hz, 1H), 8.54 (d, *J* = 4.8 Hz, 1H), 8.12 (d, *J* = 7.6 Hz, 1H), 7.80 (td, *J* = 7.6, 1.6 Hz, 1H), 7.43 – 7.34 (m, 1H), 4.77 (dd, *J* = 9.2, 7.2 Hz, 1H), 4.51 (dd, *J* = 8.4, 5.0 Hz, 1H), 3.96 – 3.85 (m, 1H), 3.79 – 3.68 (m, 4H), 2.31 – 2.14 (m, 2H), 2.11 – 1.93 (m, 3H), 1.09 (d, *J* = 6.8 Hz, 3H), 1.02 (d, *J* = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.60, 170.67, 164.38, 149.65, 148.44, 137.26, 126.30, 122.25, 58.99, 55.89, 52.27, 47.42, 31.76, 29.18, 25.12, 19.41, 18.07. HRMS (ESI): calcd. for C<sub>17</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 356.1581, found: 356.1564.

**(S)-Methyl 4-methyl-2-((S)-3-methyl-2-(picolinamido)butanamido)pentanoate (3e)**




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.64 – 8.49 (m, 2H), 8.17 (d, *J* = 8.0 Hz, 1H), 7.84 (td, *J* = 7.6, 1.6 Hz, 1H), 7.46 – 7.40 (m, 1H), 6.67 (d, *J* = 7.9 Hz, 1H), 4.65 – 4.56 (m, 1H), 4.52 (dd, *J* = 9.2, 6.8 Hz, 1H), 3.72 (s, 3H), 2.40 – 2.21 (m, 1H), 1.67 – 1.48 (m, 3H), 1.03 (t, *J* = 6.4 Hz, 6H), 0.85 (dd, *J* = 6.0, 1.2 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.38, 171.02, 164.63, 149.51, 148.47, 137.43, 126.49, 122.43, 58.71, 52.36, 50.95, 41.43, 31.30, 24.93, 22.78, 22.03, 19.46, 18.26. HRMS (ESI): calcd. for C<sub>18</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 372.1893, found: 372.1885.

**(S)-Methyl 2-cyclohexyl-2-((S)-3-methyl-2-(picolinamido)butanamido)acetate (3f)**




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.70 – 8.47 (m, 2H), 8.19 (d, *J* = 8.0 Hz, 1H), 7.92 – 7.80 (m, 1H), 7.43 (dd, *J* = 7.6, 4.8 Hz, 1H), 6.60 (d, *J* = 8.4 Hz, 1H), 4.59 – 4.44 (m, 2H), 3.73 (s, 3H), 2.35 – 2.24 (m, 1H), 1.80 – 1.46 (m, 6H), 1.21 – 0.90 (m, 11H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.34, 171.03, 164.66, 149.54, 148.47, 137.43, 126.50, 122.45, 58.87, 57.07, 52.24, 40.89, 31.17, 29.53, 28.37, 26.02, 25.99, 19.52, 18.29. HRMS (ESI): calcd. for C<sub>20</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 398.2050, found: 398.2040.

**(S)-Methyl 2-((S)-3,3-dimethyl-2-(picolinamido)butanamido)-3-methylbutanoate (3g)**




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.77 (d, *J* = 9.6 Hz, 1H), 8.57 (d, *J* = 4.4 Hz, 1H), 8.23 (d, *J* = 7.6 Hz, 1H), 7.83 (t, *J* = 7.6 Hz, 1H), 7.46 – 7.36 (m, 1H), 6.93 (d, *J* = 8.4 Hz, 1H), 4.69 (d, *J* = 9.6 Hz, 1H), 4.54 (dd, *J* = 7.6, 5.6 Hz, 1H), 3.74 (s, 3H), 2.16 – 2.05 (m, 1H), 1.09 (s, 9H), 0.85 (dd, *J* = 11.2, 6.8 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.46, 170.66, 164.28, 149.62, 148.46, 137.35, 126.37, 122.52, 60.73, 57.30, 52.15, 35.20, 31.17, 26.78, 19.04, 18.02. HRMS (ESI): calcd. for C<sub>18</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 372.1893, found: 372.1888.

**(S)-Methyl 2-((S)-3,3-dimethyl-2-(picolinamido)butanamido)-3,3-dimethylbutanoate (3h)**




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.75 (d, *J* = 9.6 Hz, 1H), 8.57 (d, *J* = 4.4 Hz, 1H), 8.25 (d, *J* = 7.6 Hz, 1H), 7.83 (t, *J* = 7.6 Hz, 1H), 7.45 – 7.35 (m, 1H), 6.95 – 6.63 (m, 1H), 4.71 – 4.55 (m, 1H), 4.44 (d, *J* = 8.8 Hz, 1H), 3.72 (s, 3H), 1.07 (s, 9H), 0.92 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.93, 170.52, 164.30, 149.63, 148.44, 137.35, 126.36, 122.56, 60.76, 60.30, 51.82, 35.21, 34.60, 26.79, 26.71. HRMS (ESI): calcd. for C<sub>19</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 386.2050, found: 386.2032.

**(2S,3S)-Methyl 2-((S)-3,3-dimethyl-2-(picolinamido)butanamido)-3-methylpentanoate (3i)**




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.77 (d, *J* = 9.6 Hz, 1H), 8.55 (d, *J* = 3.2 Hz, 1H), 8.30 – 8.15 (m, 1H), 7.90 – 7.75 (m, 1H), 7.46 – 7.35 (m, 1H), 7.25 – 6.80 (m, 1H), 4.78 – 4.65 (m, 1H), 4.62 – 4.50 (m, 1H), 3.72 (s, 3H), 1.91 – 1.75 (m, 1H), 1.42 – 1.27 (m, 1H), 1.26 – 0.99 (m, 10H), 0.88 – 0.63 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.43, 170.54, 164.20, 149.61, 148.41, 137.31, 126.31, 122.51, 60.46, 56.53, 52.02, 37.74, 35.23, 26.73, 25.32, 15.52, 11.55. HRMS (ESI): calcd. for C<sub>19</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 386.2050, found: 386.2032.

**(S)-Methyl 2-cyclohexyl-2-((S)-3,3-dimethyl-2-(picolinamido)butanamido)acetate (3j)**




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.77 (d, *J* = 9.6 Hz, 1H), 8.58 (d, *J* = 4.4 Hz, 1H), 8.21 (d, *J* = 7.6 Hz, 1H), 7.83 (t, *J* = 7.6 Hz, 1H), 7.45 – 7.37 (m, 1H), 6.77 (d, *J* = 8.4 Hz, 1H), 4.62 (d, *J* = 9.6 Hz, 1H), 4.47 (dd, *J* = 8.0, 5.6 Hz, 1H), 3.73 (s, 3H), 1.78 – 1.67 (m, 1H), 1.69 – 1.48 (m, 5H), 1.12 – 0.94 (m, 14H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.45, 170.48, 164.29, 149.60, 148.48, 137.37, 126.40, 122.50, 60.73, 57.18, 52.13, 40.66, 35.35, 29.44, 28.57, 26.77, 25.97, 25.95, 25.91. HRMS (ESI): calcd. for C<sub>21</sub>H<sub>31</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 412.2206, found: 412.2193.

**(S)-Methyl 2-((S)-3,3-dimethyl-2-(picolinamido)butanamido)-4-methylpentanoate (3k)**




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.78 (d, *J* = 10.0 Hz, 1H), 8.57 (d, *J* = 4.4 Hz, 1H), 8.19 (d, *J* = 8.0 Hz, 1H), 7.83 (t, *J* = 7.8 Hz, 1H), 7.47 – 7.36 (m, 1H), 6.96 (d, *J* = 8.0 Hz, 1H), 4.63 (d, *J* = 10.0 Hz, 1H), 4.61 – 4.53 (m, 1H), 3.73 (s, 3H), 1.64 – 1.42 (m, 3H), 1.09 (s, 9H), 0.84 – 0.77 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.49, 170.40, 164.25, 149.57, 148.51, 137.38, 126.41, 122.46, 60.59, 52.26, 50.91, 41.30, 35.37, 26.74, 24.86, 22.65, 22.07. HRMS (ESI): calcd. for C<sub>19</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 386.2050, found: 386.2032.

**Methyl (S)-3,3-dimethyl-2-((S)-2-(picolinamido)butanamido)butanoate (3l)**



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56 (d, *J* = 4.4 Hz, 1H), 8.46 (d, *J* = 8.0 Hz, 1H), 8.19 (d, *J* = 7.6 Hz, 1H), 7.91 – 7.78 (m, 1H), 7.50 – 7.38 (m, 1H), 6.90 (d, *J* = 9.2 Hz, 1H), 4.60 (q, *J* = 7.6 Hz, 1H), 4.44 (d, *J* = 9.2 Hz, 1H), 3.72 (s, 3H), 2.09 – 1.93 (m, 1H), 1.88 – 1.75 (m, 1H), 0.99 (t, *J* = 7.2 Hz, 3H), 0.93 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.92, 171.27, 164.77, 149.38, 148.45, 137.50, 126.58, 122.43, 60.35, 54.80, 51.94, 34.76, 26.65, 25.32, 10.27. HRMS (ESI): calcd. for C<sub>17</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>Na (M + Na)<sup>+</sup>: 358.1737, found: 358.1731.


**(S)-Methyl 1-((2S,3S)-3-methoxy-2-(picolinamido)butanoyl)pyrrolidine-2-carboxylate (3m)**



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.78 (d, *J* = 8.0 Hz, 1H), 8.55 – 8.50 (m, 1H), 8.12 – 8.05 (m, 1H), 7.82 – 7.74 (m, 1H), 7.41 – 7.34 (m, 1H), 4.90 (dd, *J* = 8.0, 5.2 Hz, 1H), 4.52 (dd, *J* = 8.8, 5.2 Hz, 1H), 3.92 – 3.73 (m, 3H), 3.71 (s, 3H), 3.42 (s, 3H), 2.26 – 2.14 (m, 1H), 2.10 – 2.02 (m, 1H), 2.00 – 1.91 (m, 2H), 1.28 (d, *J* = 6.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.49, 168.88, 164.39, 149.56, 148.46,


137.19, 126.30, 122.15, 77.63, 59.14, 57.18, 55.11, 52.24, 47.55, 29.12, 25.18, 15.88. **HRMS (ESI):** calcd. for  $C_{17}H_{23}N_3O_5Na$  ( $M + Na$ )<sup>+</sup>: 372.1529, found: 372.1517.

**(S)-Methyl 2-((2S,3S)-3-methoxy-2-(picolinamido)butanamido)-3,3-dimethylbutanoate (3n)**



**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.85 (d,  $J$  = 6.4 Hz, 1H), 8.61 – 8.56 (m, 1H), 8.15 (dd,  $J$  = 8.0 Hz, 0.8 Hz, 1H), 7.88 – 7.79 (m, 1H), 7.46 – 7.40 (m, 1H), 7.32 – 7.25 (m, 1H), 4.81 – 4.71 (m, 1H), 4.38 (dd,  $J$  = 8.8, 1.6 Hz, 1H), 4.11 – 3.96 (m, 1H), 3.74 – 3.66 (m, 3H), 3.52 – 3.46 (m, 3H), 1.16 (dd,  $J$  = 6.4, 1.6 Hz, 3H), 0.98 (d,  $J$  = 1.6 Hz, 9H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 171.74, 169.56, 164.86, 149.53, 148.61, 137.37, 126.54, 122.28, 76.05, 60.70, 57.08, 56.14, 51.83, 34.45, 26.69, 14.30. **HRMS (ESI):** calcd. for  $C_{18}H_{27}N_3O_5Na$  ( $M + Na$ )<sup>+</sup>: 388.1842, found: 388.1826.


**(S)-Methyl 2-((S)-3,3-dimethyl-2-((S)-3-methyl-2-(picolinamido)butanamido)-3,3-dimethylbutanoate (5a)**



**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.61 – 8.51 (m, 2H), 8.21 (d,  $J$  = 7.2 Hz, 1H), 7.82 (t,  $J$  = 6.4 Hz, 1H), 7.50 – 7.32 (m, 1H), 7.02 – 6.83 (m, 1H), 6.78 – 6.52 (m, 1H), 4.65 – 4.49 (m, 1H), 4.43 (d,  $J$  = 8.5 Hz, 2H), 3.70 (s, 3H), 2.31 – 2.20 (m, 1H), 1.10 – 0.70 (m, 24H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 171.81, 171.32, 170.33, 164.55, 149.55, 148.32, 137.41, 126.39, 122.61, 60.77, 60.18, 58.95, 51.86, 34.75, 34.65, 31.14, 26.66, 26.64, 19.44, 18.37. **HRMS (ESI):** calcd. for  $C_{24}H_{38}N_4O_5Na$  ( $M + Na$ )<sup>+</sup>:

485.2734, found: 485.2718.


**(S)-Methyl 2-((S)-2-((S)-3,3-dimethyl-2-(picolinamido)butanamido)-3,3-dimethylbutanamido)-3-methylbutanoate (5b)**



**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.73 (d,  $J$  = 9.6 Hz, 1H), 8.57 – 8.52 (m, 1H), 8.25 (dd,  $J$  = 7.6, 4.8 Hz, 1H), 7.84 – 7.76 (m, 1H), 7.43 – 7.35 (m, 1H), 6.81 (dd,  $J$  = 24.8, 8.8 Hz, 1H), 6.45 (dd,  $J$  = 30.8, 8.4 Hz, 1H), 4.73 – 4.50 (m, 2H), 4.31 (dd,  $J$  = 8.8, 4.8 Hz, 1H), 3.80 – 3.65 (m, 3H), 2.22 – 2.07 (m, 1H), 1.08 – 1.00 (m, 9H), 0.96 – 0.85 (m, 15H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 172.36, 172.33, 170.55, 170.53, 170.39, 170.36, 164.22, 149.63, 148.34, 137.38, 126.30,

122.73, 122.68, 60.91, 60.46, 57.11, 52.25, 35.30, 34.61, 31.24, 26.81, 26.65, 19.03, 17.86. **HRMS (ESI):** calcd. for  $C_{24}H_{38}N_4O_5Na$  ( $M + Na$ )<sup>+</sup>: 485.2734, found: 485.2714.

**(S)-Methyl 2-((S)-2-((S)-3,3-dimethyl-2-(picolinamido)butanamido)-3,3-dimethylbutanamido)-3,3-dimethylbutanoate (5c)**




**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.72 (d,  $J$  = 9.6 Hz, 1H), 8.61 – 8.53 (m, 1H), 8.22 (dd,  $J$  = 7.6, 0.8 Hz, 1H), 7.82 (td,  $J$  = 7.6, 1.2 Hz, 1H), 7.45 – 7.36 (m, 1H), 6.75 – 6.60 (m, 1H), 6.40 – 6.20 (m, 1H), 4.59 – 4.51 (m, 1H), 4.45 (d,  $J$  = 9.2 Hz, 1H), 4.28 (d,  $J$  = 9.0 Hz, 1H), 3.72 (s, 3H), 1.05 (s, 9H), 0.96 (s, 9H), 0.92 (s, 9H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 171.80, 170.54, 170.13, 164.26, 149.66, 148.39, 137.38, 126.34, 122.62, 61.05, 61.02, 60.12, 51.95, 35.28, 34.84, 26.82, 26.68.

**HRMS (ESI):** calcd. for  $C_{25}H_{40}N_4O_5Na$  ( $M + Na$ )<sup>+</sup>: 499.2891, found: 499.2865.

**(S)-Methyl 1-((S)-2-((S)-3,3-dimethyl-2-(picolinamido)butanamido)-3,3-dimeth-**


**ylbutanoyl)pyrrolidine-2-carboxylate (5d)**



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.70 (d, *J* = 9.2 Hz, 1H), 8.60 – 8.45 (m, 1H), 8.18 (d, *J* = 7.8 Hz, 1H), 7.81 (t, *J* = 7.2 Hz, 1H), 7.46 – 7.34 (m, 1H), 6.60 – 6.40 (m, 1H), 4.59 (d, *J* = 8.8 Hz, 1H), 4.52 – 4.38 (m, 2H), 3.99 – 3.85 (m, 1H), 3.81 – 3.60 (m, 4H), 2.3 – 1.85 (m, 4H), 1.15 – 0.90 (m, 18H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.65, 170.45, 170.00, 164.22, 149.62, 148.39, 137.38, 126.35, 122.51, 61.04, 58.96, 57.27, 52.20, 48.11, 35.40, 35.30, 29.23, 26.89, 26.50, 25.28. HRMS (ESI): calcd. for

C<sub>24</sub>H<sub>36</sub>N<sub>4</sub>O<sub>5</sub>Na (M + Na)<sup>+</sup>: 483.2577, found: 483.2547.


**(S)-Methyl 1-((S)-2-((S)-3,3-dimethyl-2-((2S,3S)-3-methyl-2-(picolinamido)pentanamido)butanamido)-3-methylbutanoyl)pyrrolidine-2-carboxylate (5i)**



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56 (d, *J* = 7.2 Hz, 2H), 8.17 (d, *J* = 8.0 Hz, 1H), 7.83 (t, *J* = 7.6 Hz, 1H), 7.48 – 7.37 (m, 1H), 6.75 – 6.65 (m, 1H), 6.55 – 6.35 (m, 1H), 4.68 – 4.58 (m, 1H), 4.54 – 4.49 (m, 1H), 4.27 (d, *J* = 8.8 Hz, 1H), 3.83 – 3.59 (m, 5H), 2.29 – 2.18 (m, 1H), 2.14 – 2.07 (m, 1H), 2.01 – 1.91 (m, 3H), 1.64 – 1.51 (m, 1H), 1.23 – 1.13 (m, 1H), 1.06 – 0.81 (m, 21H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.48, 171.03,

170.33, 170.32, 164.53, 149.56, 148.40, 137.39, 126.40, 122.47, 61.06, 58.88, 58.22, 55.53, 52.29, 47.35, 37.38, 34.75, 31.23, 29.13, 26.75, 25.11, 25.08, 19.37, 17.50, 15.67, 11.35. HRMS (ESI): calcd. for C<sub>29</sub>H<sub>45</sub>N<sub>5</sub>O<sub>6</sub>Na (M + Na)<sup>+</sup>: 582.3262, found: 582.3223.

**Methyl ((S)-2-((S)-3,3-dimethyl-2-((S)-3-methyl-2-(picolinamido)butanamido)-3,3-dimethylbutanoyl)-L-valinate (5j)**




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.69 (d, *J* = 9.6 Hz, 1H), 8.62 – 8.53 (m, 1H), 8.31 (d, *J* = 8.0 Hz, 1H), 8.07 (d, *J* = 10.4 Hz, 1H), 7.90 – 7.82 (m, 1H), 7.79 – 7.68 (m, 1H), 7.44 – 7.39 (m, 1H), 6.25 (d, *J* = 9.2 Hz, 1H), 5.09 – 4.98 (m, 1H), 4.79 – 4.67 (m, 1H), 4.60 (dd, *J* = 9.2, 5.2 Hz, 1H), 4.48 (dd, *J* = 9.6, 2.0 Hz, 1H), 3.74 (s, 3H), 2.20 – 2.05 (m, 2H), 1.01 (s, 9H), 0.96 (s, 9H), 0.93 – 0.85 (m, 9H), 0.78 (d, *J* = 6.8 Hz, 3H). <sup>13</sup>C NMR (101

MHz, CDCl<sub>3</sub>) δ 172.78, 171.65, 170.71, 170.66, 164.42, 149.61, 148.46, 137.48, 126.42, 122.79, 61.11, 60.24, 57.84, 57.14, 52.17, 35.66, 33.91, 32.37, 31.21, 27.05, 26.63, 19.45, 19.27, 18.21, 17.95. HRMS (ESI): calcd. for C<sub>29</sub>H<sub>47</sub>N<sub>5</sub>O<sub>6</sub>Na (M + Na)<sup>+</sup>: 584.3418, found: 584.3399.

### 3. Optimization of Reaction Conditions

**Table S1:** Optimization by varying different bases



Entry	Base	Yield (%) <sup>a</sup>
1	---	32 (mono)
2	KHF <sub>2</sub>	84 (m/d=3.9:1) <sup>b</sup>
3	Na <sub>2</sub> CO <sub>3</sub>	71 (m/d=2.5:1)
4	NaHCO <sub>3</sub>	60 (m/d=3.0:1)
5	Na <sub>3</sub> PO <sub>4</sub>	70 (m/d=2.5:1)
6	K <sub>2</sub> HPO <sub>4</sub>	70 (m/d=2.7:1)

<sup>a</sup> <sup>1</sup>H NMR yield using 1,3,5-trimethoxybenzene as the internal standard. <sup>b</sup> Isolated yield.

**Table S2:** Optimization by varying different ligands.

CC(C)[C@H](NHPA)C(=O)OC (1a)  $\xrightarrow[\text{DCE, 100 } ^\circ\text{C, 24 h}]{\text{Pd(OAc)}_2 \text{ (10 mol\%)}, \text{Ligand (20 mol\%)}, (\text{SiMe}_3)_2, \text{Ag}_2\text{CO}_3 \text{ (3 eq)}, \text{KHF}_2 \text{ (3 eq)}}$  CC(C)[C@H](NHPA)C(=O)OC (2a, mono) + CC(C)[C@@H](NHPA)C(=O)OC (2a', di)

Entry	Ligand	Yield (%) <sup>a</sup>
1	---	16 (mono)
2	BQ	73 (m/d=3.1:1)
3	2,6-DiClBQ	84 (m/d=3.9:1) <sup>b</sup>
4	2,6-DiOMeBQ	66 (m/d=2.7:1)
5	2-CINQ	78 (m/d=3.4:1)
6	Dichlone	88 (m/d=1.7:1, 99% ee) <sup>b,c</sup>
7	TFBQ	trace
8	3,5-DiTB-1,2-BQ	trace
9	Chloranilic acid	trace

BQ

2,6-DiClBQ

2,6-DiOMeBQ

2-CINQ

Dichlone

TFBQ

3,5-DiTB-1,2-BQ

Chloranilic acid

<sup>a</sup> <sup>1</sup>H NMR yield using 1,3,5-trimethoxybenzene as the internal standard. <sup>b</sup> Isolated yield. <sup>c</sup> The ee value was determined by HPLC. BQ = benzoquinone; 2,6-DiClBQ = 2,6-dichloro-1,4-benzoquinone; 2,6-DiOMeBQ = 2,6-dimethoxy-1,4-benzoquinone; 2-CINQ = 2-chloro-1,4-naphthoquinone. Dichlone = 2,3-Dichloro-1,4-naphthoquinone. TFBQ = Tetrafluoro-1,4-benzoquinone; 3,5-DiTB-1,2-BQ = 3,5-di-*tert*-butylcyclohexa-3,5-diene-1,2-dione

**Table S3:** Optimization by varying different solvents.

Entry	Solvent	Yield (%) <sup>a</sup>
1	DCE	88 (m/d=1.7:1) <sup>b</sup>
2	Toluene	36 (mono)
3	MeCN	0
4	<i>t</i> -BuOH	trace
5	Dioxane	trace
6	DCE	0 <sup>[c]</sup>

<sup>a</sup> <sup>1</sup>H NMR yield using 1,3,5-trimethoxybenzene as the internal standard. <sup>b</sup> Isolated yield. <sup>c</sup>Without Pd(OAc)<sub>2</sub>.


**Table S4:** Optimization by varying different oxidants.

Entry	Oxidant	Yield (%) <sup>a</sup>
1	---	0
2	Ag <sub>2</sub> CO <sub>3</sub>	88 (m/d=1.7:1) <sup>b</sup>
3	AgOAc	0
4	Ag <sub>2</sub> SO <sub>4</sub>	10 (mono)
5	Ag <sub>2</sub> O	15 (mono)
6	Ag <sub>3</sub> PO <sub>3</sub>	trace
7	BQ	10 (mono)

<sup>a</sup> <sup>1</sup>H NMR yield using 1,3,5-trimethoxybenzene as the internal standard. <sup>b</sup> Isolated yield.




#### 4. General Procedure (GP-2) for $\gamma$ -C(sp<sup>3</sup>)-H silylation



To a 50 mL Schlenk tube were added amine derivative **1** (23.6 mg, 0.1 mmol, 1.0 equiv), Pd(OAc)<sub>2</sub> (2.3 mg, 10 mol%), hexamethyldisilane (3.0 equiv), dichlorone (4.5 mg, 0.2 equiv), Ag<sub>2</sub>CO<sub>3</sub> (82.5 mg, 3.0 equiv), KHF<sub>2</sub> (23.4 mg, 3.0 equiv), 1,1-dichloroethane (1.0 mL). The mixture was then stirred at 100 °C for 24 hours. After being cooled to room temperature, the reaction was diluted with DCM and filtered through a pad of Celite, which was washed with DCM. The solvent was removed under vacuum directly and the crude product was purified by silica gel column chromatography to afford the desired product **2a** and **2a'**.


##### (2S,3S)-methyl 3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanoate (**2a**)



The compound **2a** was prepared according to the GP-2 with starting materials **1a**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2a** was obtained as a colorless oil (16.8 mg, 55%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.68 – 8.57 (m, 1H), 8.53 (d, *J* = 9.2 Hz, 1H), 8.22 – 8.14 (m, 1H), 7.84 (td, *J* = 7.6, 1.6 Hz, 1H), 7.48 – 7.39 (m, 1H), 4.78 – 4.72 (m, 1H), 3.80 – 3.72 (m, 3H), 2.42 – 2.26 (m, 1H), 1.08 – 0.96 (m, 3H), 0.81 – 0.62 (m, 1H), 0.57 – 0.44 (m, 1H), 0.05 – 0 (m, 9H).

**Major:** <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  172.33, 164.49, 149.64, 148.40, 137.42, 126.44, 122.47, 58.98, 52.26, 33.09, 19.57, 19.28, -0.81. **Minor:** <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  172.30, 164.49, 149.64, 148.40, 137.42, 126.44, 122.47, 58.98, 52.28, 33.09, 21.18, 18.06, -0.71. **HRMS (ESI):** calcd. for C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub>SiNa (M + Na)<sup>+</sup>: 331.1448, found: 331.1443; Enantiomeric excess was determined by HPLC with a Daicel Chiralpak IB-N5, n-hexane/2-propanol = 97/3,  $v$  = 0.8 ml/min,  $\lambda$  = 254 nm, *t* (minor) = 14.9 min, *t* (major) = 16.1 min, *t* (minor) = 21.2 min, 99% ee, d.r. = 4.4:1.


##### Methyl (S)-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanoate (**2a'**)



The compound **2a'** was prepared according to the GP-2 with starting materials **1a**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2a'** was obtained as a colorless oil (12.5 mg, 33%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.66 – 8.58 (m, 1H), 8.53 (d, *J* = 9.2 Hz, 1H), 8.19 (dt, *J* = 7.8, 1.1 Hz, 1H), 7.84 (td, *J* = 7.6, 1.2 Hz, 1H), 7.49 – 7.42 (m, 1H), 4.80 (dd, *J* = 9.2, 2.8 Hz, 1H), 3.75 (s, 3H), 2.49 – 2.38 (m, 1H), 0.81 (dd, *J* = 15.2, 10.0 Hz, 1H), 0.74 – 0.59 (m, 2H), 0.48 (dd, *J* = 14.8, 4.0 Hz, 1H), 0.12 – 0.04 (m, 18H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  172.44, 164.67, 149.78, 148.42, 137.42, 126.42, 122.46, 57.58, 52.31, 33.75, 21.74, 21.00, -0.68, -0.73.

**HRMS (ESI):** calcd. for C<sub>18</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub>Si<sub>2</sub>Na (M + Na)<sup>+</sup>: 403.1843, found: 403.1848.


##### (2S,3S)-tert-butyl 3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanoate (**2b**)



The compound **2b** was prepared according to the GP-2 with starting materials **1b**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2b** was obtained as a colorless oil (17.8 mg, 50%, d.r. = 3:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.70 – 8.48 (m, 2H), 8.17 (dt, *J* = 7.6, 1.2 Hz, 1H), 7.83 (td, *J* = 7.6, 1.6 Hz, 1H), 7.46 – 7.38 (m, 1H), 4.72 – 4.59 (m, 1H), 2.41 – 2.25 (m, 1H), 1.48 (s, 9H), 1.02 (d, *J* =


6.8 Hz, 3H), 0.85 – 0.62 (m, 1H), 0.56 – 0.40 (m, 1H), 0.06 – 0 (m, 9H). **Major:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.09, 164.43, 149.91, 148.42, 137.35, 126.30, 122.40, 81.95, 59.21, 33.40, 28.26, 19.54, 19.14, -0.62. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.03, 164.37, 149.91, 148.42, 137.35, 126.30, 122.40, 81.95, 59.25, 33.35, 28.23, 21.04, 18.05, -0.70. **HRMS (ESI):** calcd. for  $\text{C}_{18}\text{H}_{30}\text{N}_2\text{O}_3\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 373.1917, found: 373.1917.

***tert*-Butyl (S)-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanoate (2b')**




The compound **2b'** was prepared according to the **GP-2** with starting materials **1b**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2b'** was obtained as a colorless oil (2.7 mg, 7%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.63 – 8.45 (m, 2H), 8.18 (d,  $J$  = 7.6 Hz, 1H), 7.83 (t,  $J$  = 7.6 Hz, 1H), 7.42 (dd,  $J$  = 7.6, 4.8 Hz, 1H), 4.69 (dt,  $J$  = 9.2, 1.6 Hz, 1H), 2.48 – 2.37 (m, 1H), 1.49 (s, 9H), 0.82 – 0.72 (m, 2H), 0.64 (dd,  $J$  = 14.4, 10.0 Hz, 1H), 0.44 (dd,  $J$  = 14.8, 4.0 Hz, 1H), 0.08 (d,  $J$  = 3.2 Hz, 18H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.17, 164.52, 150.00, 148.42, 137.34, 126.27, 122.36, 81.84, 57.78, 34.22, 28.28, 21.23, 20.90, -0.46, -0.69. **HRMS (ESI):** calcd. for  $\text{C}_{21}\text{H}_{38}\text{N}_2\text{O}_3\text{Si}_2\text{Na}$  ( $\text{M} + \text{Na}$ ) $^+$ : 445.2313, found: 445.2323.

**Methyl (2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)pentanoate (2c)**




The compound **2c** was prepared according to the **GP-2** with starting materials **1c**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2c** was obtained as a colorless oil (20.1 mg, 62%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.63 – 8.56 (m, 1H), 8.52 (d,  $J$  = 9.2 Hz, 1H), 8.17 (dt,  $J$  = 8.0, 1.2 Hz, 1H), 7.84 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.48 – 7.40 (m, 1H), 4.83 (dd,  $J$  = 9.2, 4.0 Hz, 1H), 3.76 (s, 3H), 2.16 – 2.05 (m, 1H), 1.58 – 1.35 (m, 2H), 0.99 (t,  $J$  = 7.2 Hz, 3H), 0.67 (dd,  $J$  = 14.8, 6.0 Hz, 1H), 0.52 (dd,  $J$  = 14.8, 7.6 Hz, 1H), 0.03 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.45, 164.36, 149.67, 148.40, 137.43, 126.43, 122.42, 56.25, 52.26, 39.36, 25.75, 17.89, 11.60, -0.83. **HRMS (ESI):** calcd. for  $\text{C}_{16}\text{H}_{26}\text{N}_2\text{O}_3\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 345.1604, found: 345.1600.

**Ethyl (2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)pentanoate (2d)**



The compound **2d** was prepared according to the **GP-2** with starting materials **1d**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2d** was obtained as a colorless oil (16.4 mg, 49%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.64 – 8.49 (m, 2H), 8.17 (dt,  $J$  = 7.6, 1.2 Hz, 1H), 7.84 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.46 – 7.38 (m, 1H), 4.81 (dd,  $J$  = 9.2, 4.4 Hz, 1H), 4.30 – 4.15 (m, 2H), 2.16 – 2.03 (m, 1H), 1.57 – 1.46 (m, 1H), 1.46 – 1.36 (m, 1H), 1.29 (t,  $J$  = 7.2 Hz, 3H), 0.99 (t,  $J$  = 7.4 Hz, 3H), 0.69 (dd,  $J$  = 14.8, 6.0 Hz, 1H), 0.52 (dd,  $J$  = 14.8, 8.0 Hz, 1H), 0.03 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.95, 164.32, 149.74, 148.40, 137.40, 126.38, 122.38, 61.27, 56.19, 39.48, 25.79, 17.86, 14.39, 11.63, -0.83. **HRMS (ESI):** calcd. for  $\text{C}_{17}\text{H}_{28}\text{N}_2\text{O}_3\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 359.1761, found: 359.1758.


***tert*-Butyl (2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)pentanoate (2e)**



The compound **2e** was prepared according to the **GP-2** with starting materials **1e**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2e** was obtained as a colorless oil (16.8 mg, 47%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.65 – 8.50 (m, 2H), 8.17 (dt,  $J$  = 8.0, 1.2 Hz, 1H), 7.83 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.45 – 7.38 (m, 1H), 4.73 (dd,  $J$  = 8.8, 3.6 Hz, 1H), 2.12 – 1.97 (m, 1H), 1.58 – 1.45 (m, 10H), 1.44 – 1.36 (m, 1H), 1.01 (t,  $J$  = 7.6 Hz, 3H), 0.72 (dd,  $J$  = 14.8, 6.0 Hz, 1H), 0.48 (dd,  $J$


= 14.8, 7.6 Hz, 1H), 0.02 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.09, 164.19, 149.90, 148.41, 137.35, 126.28, 122.30, 81.96, 56.35, 39.78, 28.27, 28.24, 26.02, 17.79, 11.83, -0.84. HRMS (ESI): calcd. for  $\text{C}_{19}\text{H}_{32}\text{N}_2\text{O}_3\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 387.2074, found: 387.2068.

### Benzyl (2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)pentanoate (2f)




The compound **2f** was prepared according to the GP-2 with starting materials **1f**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2f** was obtained as a colorless oil (17 mg, 43%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.64 – 8.49 (m, 2H), 8.18 (dt,  $J$  = 7.6, 1.2 Hz, 1H), 7.84 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.47 – 7.40 (m, 1H), 7.40 – 7.28 (m, 5H), 5.30 – 5.23 (m, 1H), 5.19 – 5.13 (m, 1H), 4.87 (dd,  $J$  = 9.2, 4.4 Hz, 1H), 2.17 – 2.04 (m, 1H), 1.50 – 1.33 (m, 2H), 0.94 (t,  $J$  = 7.6 Hz, 3H), 0.65 (dd,  $J$  = 14.8, 6.0 Hz, 1H), 0.47 (dd,  $J$  = 14.8, 8.0 Hz, 1H), 0.05 – 0 (m, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.84, 164.36, 149.68, 148.39, 137.41, 135.74, 128.67, 128.44, 128.42, 126.42, 122.40, 66.97, 56.25, 39.50, 25.66, 17.79, 11.48, -0.85. HRMS (ESI): calcd. for  $\text{C}_{22}\text{H}_{30}\text{N}_2\text{O}_3\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 429.1917, found: 429.1920.

### Methyl (2S,3R)-3-(tert-butoxy)-2-(picolinamido)-4-(trimethylsilyl)butanoate (2g)




The compound **2g** was prepared according to the GP-2 with starting materials **1g**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2g** was obtained as a colorless oil (21.3 mg, 58%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.69 (d,  $J$  = 9.6 Hz, 1H), 8.64 – 8.57 (m, 1H), 8.17 (dt,  $J$  = 7.6, 1.2 Hz, 1H), 7.82 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.45 – 7.37 (m, 1H), 4.66 (d,  $J$  = 9.2 Hz, 1H), 4.32 (dt,  $J$  = 11.6, 2.0 Hz, 1H), 3.72 (s, 3H), 1.25 – 1.11 (m, 10H), 0.95 – 0.78 (m, 1H), 0.10 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.63, 165.13, 149.86, 148.58, 137.23, 126.31, 122.48, 74.29, 69.43, 57.56, 52.37, 28.56, 24.45, -0.73. HRMS (ESI): calcd. for  $\text{C}_{18}\text{H}_{30}\text{N}_2\text{O}_4\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 389.1867, found: 389.1861.

### Methyl (S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butanoate (2h)




The compound **2h** was prepared according to the GP-2 with starting materials **1h**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2h** was obtained as a colorless oil (16.1 mg, 50%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.68 – 8.54 (m, 2H), 8.17 (dt,  $J$  = 7.6, 1.2 Hz, 1H), 7.84 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.47 – 7.39 (m, 1H), 4.64 (d,  $J$  = 9.6 Hz, 1H), 3.74 (s, 3H), 1.11 (d,  $J$  = 9.6 Hz, 6H), 0.90 – 0.74 (m, 2H), 0.11 – 0.04 (m, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.00, 164.23, 149.67, 148.43, 137.43, 126.43, 122.51, 62.12, 51.90, 38.09, 28.00, 26.92, 26.71, 1.07. HRMS (ESI): calcd. for  $\text{C}_{16}\text{H}_{26}\text{N}_2\text{O}_3\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 345.1604, found: 345.1600.

### Methyl (S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanoate (2h')




The compound **2h'** was prepared according to the GP-2 with starting materials **1h**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2h'** was obtained as a colorless oil (8.8 mg, 23%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.68 – 8.56 (m, 2H), 8.17 (dt,  $J$  = 8.0, 1.2 Hz, 1H), 7.84 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.48 – 7.40 (m, 1H), 4.78 (d,  $J$  = 9.6 Hz, 1H), 3.75 (s, 3H), 1.16 (s, 3H), 1.02 (d,  $J$  = 14.8 Hz, 1H), 0.98 – 0.90 (m, 2H), 0.79 (d,  $J$  = 14.8 Hz, 1H), 0.15 – 0.05 (m, 18H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.11, 164.36, 149.72, 148.46, 137.44, 126.42, 122.46, 61.43, 51.86, 40.90, 29.35, 29.05, 27.41, 1.22, 1.15. HRMS (ESI): calcd. for  $\text{C}_{19}\text{H}_{34}\text{N}_2\text{O}_3\text{Si}_2\text{Na}$  ( $\text{M} + \text{Na}$ ) $^+$ : 417.2000, found: 417.1996.

### Methyl (S)-2-(picolinamido)-4-(trimethylsilyl)butanoate (2i)




The compound **2i** was prepared according to the **GP-2** with starting materials **1i**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2i** was obtained as a colorless oil (17.6 mg, 60%). **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.65 – 8.57 (m, 1H), 8.49 (d, *J* = 8.8 Hz, 1H), 8.17 (dt, *J* = 8.0, 1.2 Hz, 1H), 7.84 (td, *J* = 7.6, 2.0 Hz, 1H), 7.49 – 7.40 (m, 1H), 4.84 – 4.74 (m, 1H), 3.77 (s, 3H), 2.02 – 1.89 (m, 1H), 1.88 – 1.77 (m, 1H), 0.65 – 0.45 (m, 2H), -0.02 (s, 9H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 172.78, 164.22, 149.62, 148.39, 137.44, 126.47, 122.46, 54.64, 52.43, 27.44, 11.93, -1.79. **HRMS (ESI)**: calcd. for C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>SiNa (M + Na)<sup>+</sup>: 317.1291, found: 317.1284.

### (S)-methyl 2-(picolinamido)-5-(trimethylsilyl)pentanoate (2j)




The compound **2j** was prepared according to the **GP-2** with starting materials **1j**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2j** was obtained as a colorless oil (3.5mg, 11%). **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.62 – 8.55 (m, 1H), 8.42 (d, *J* = 8.2 Hz, 1H), 8.24 – 8.14 (m, 1H), 7.84 (td, *J* = 7.6, 1.6 Hz, 1H), 7.49 – 7.38 (m, 1H), 4.90 – 4.68 (m, 1H), 3.82 – 3.73 (m, 3H), 2.08 – 1.93 (m, 1H), 1.92 – 1.75 (m, 1H), 1.43 – 1.36 (m, 1H), 1.07 – 0.95 (m, 1H), 0.91 – 0.46 (m, 2H), 0.00 – -0.07 (m, 9H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 173.05, 148.39, 137.44, 126.47, 122.46, 52.44, 52.20, 36.40, 20.15, 16.36, -1.58. **HRMS (ESI)**: calcd. for C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>SiH (M + H)<sup>+</sup>: 309.1629, found: 309.1631.

### (S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butyl acetate (2k)



The compound **2k** was prepared according to the **GP-2** with starting materials **1k**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2k** was obtained as a colorless oil (11.8 mg, 35%). **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.58 (d, *J* = 4.8 Hz, 1H), 8.24 – 8.05 (m, 2H), 7.90 – 7.78 (m, 1H), 7.46 – 7.39 (m, 1H), 4.42 – 4.32 (m, 1H), 4.28 – 4.14 (m, 2H), 1.97 (s, 3H), 1.07 (d, *J* = 11.2 Hz, 6H), 0.79 (s, 2H), 0.08 (s, 9H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 171.44, 164.56, 149.91, 148.26, 137.50, 126.30, 122.53, 64.16, 57.79, 37.26, 28.34, 27.20, 26.81, 21.07, 1.12. **HRMS (ESI)**: calcd. for C<sub>17</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub>SiH (M + H)<sup>+</sup>: 359.1761, found: 359.1755.


### (S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butyl acetate (2k')



The compound **2k'** was prepared according to the **GP-2** with starting materials **1k** and **2a**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2k'** was obtained as a colorless oil (7.2 mg, 18%). **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.64 – 8.57 (m, 1H), 8.20 (dt, *J* = 8.0, 1.2 Hz, 1H), 8.13 (d, *J* = 10.0 Hz, 1H), 7.85 (td, *J* = 7.6, 1.6 Hz, 1H), 7.47 – 7.38 (m, 1H), 4.46 – 4.38 (m, 1H), 4.33 – 4.16 (m, 2H), 1.97 (s, 3H), 1.10 (s, 3H), 0.98 – 0.87 (m, 3H), 0.73 (d, *J* = 14.4 Hz, 1H), 0.19 – 0.05 (m, 18H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 171.57, 164.64, 149.95, 148.28, 137.52, 126.29, 122.48, 64.49, 57.13, 40.47, 30.14, 29.17, 27.82, 21.07, 1.31, 1.19. **HRMS (ESI)**: calcd. for C<sub>20</sub>H<sub>36</sub>N<sub>2</sub>O<sub>3</sub>Si<sub>2</sub>Na (M + Na)<sup>+</sup>: 431.2056, found: 431.2052.

### (2S,3S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)butyl acetate (2l)


The compound **2l** was prepared according to the **GP-2** with starting materials **1l**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2l** was obtained as a colorless oil (16.9 mg, 53%, d.r. = 3:1), diastereomeric ratio was determined by <sup>1</sup>H NMR. **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.59 – 8.52 (m,



1H), 8.19 (dt,  $J = 8.0, 1.2$  Hz, 1H), 8.12 (d,  $J = 8.8$  Hz, 1H), 7.85 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.46 – 7.39 (m, 1H), 4.30 – 4.14 (m, 3H), 2.15 – 1.95 (m, 4H), 1.82 – 1.66 (m, 1H), 1.05 – 0.97 (m, 3H), 0.79 – 0.73 (m, 1H), 0.51 – 0.41 (m, 1H), 0.03 – 0 (m, 9H). **Major:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.20, 164.45, 149.92, 148.25, 137.48, 126.32, 122.47, 64.36, 54.42, 31.25, 21.02, 19.53, 19.39, -0.67. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.20, 164.40, 149.92, 148.25, 137.48, 126.32, 122.48, 64.70, 54.58, 31.15, 21.37, 19.53, 18.22, -0.65. **HRMS (ESI):** calcd. for  $\text{C}_{16}\text{H}_{26}\text{N}_2\text{O}_3\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ :

345.1604, found: 345.1595.


### (S)-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butyl acetate (2l')



The compound **2l'** was prepared according to the **GP-2** with starting materials **1l**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2l'** was obtained as a colorless oil (6.0 mg, 16%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.61 – 8.55 (m, 1H), 8.20 (dt,  $J = 8.0, 1.2$  Hz, 1H), 8.14 (d,  $J = 9.6$  Hz, 1H), 7.85 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.47 – 7.40 (m, 1H), 4.45 – 4.32 (m, 1H), 4.15 (dd,  $J = 6.8, 1.6$  Hz, 2H), 2.18 – 2.08 (m, 1H), 2.03 (s, 3H), 0.82 – 0.70 (m, 2H), 0.58 (dd,  $J = 14.2, 8.8$  Hz, 1H), 0.48 (dd,  $J = 14.8, 4.8$  Hz, 1H), 0.15 – 0.02 (m, 18H).  $^{13}\text{C}$  NMR (101


MHz,  $\text{CDCl}_3$ )  $\delta$  171.13, 164.48, 150.03, 148.27, 137.48, 126.30, 122.41, 64.12, 52.62, 31.72, 21.62, 21.00, 20.19, -0.54. **HRMS (ESI):** calcd. for  $\text{C}_{19}\text{H}_{34}\text{N}_2\text{O}_3\text{Si}_2\text{Na}$  ( $\text{M} + \text{Na}$ ) $^+$ : 417.2000, found: 417.2005.

### N-((2S,3S)-1-(benzyloxy)-3-((trimethylsilyl)methyl)pentan-2-yl)picolinamide (2m)



The compound **2m** was prepared according to the **GP-2** with starting materials **1m**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2m** was obtained as a colorless oil (14 mg, 37%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.60 – 8.52 (m, 1H), 8.31 – 8.16 (m, 2H), 7.84 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.45 – 7.37 (m, 1H), 7.35 – 7.20 (m, 5H), 4.62 – 4.45 (m, 2H), 4.32 – 4.21 (m, 1H), 3.74 – 3.64 (m, 1H), 3.60 – 3.52 (m, 1H), 2.15 – 1.85 (m, 1H), 1.55 – 1.33 (m, 2H), 0.91 (t,  $J = 7.6$  Hz, 3H), 0.65 (dd,  $J = 14.8, 5.2$  Hz, 1H), 0.55 (dd,  $J = 14.8, 8.4$  Hz, 1H), 0.02 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  164.10, 150.28, 148.20, 138.50, 137.40, 128.44, 127.74, 127.66, 126.11, 122.38, 73.14, 70.06, 52.59, 36.55, 24.88, 17.48, 10.85, -0.58. **HRMS (ESI):** calcd. for  $\text{C}_{22}\text{H}_{32}\text{N}_2\text{O}_2\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 407.2125, found: 407.2119.


### (2S,3S)-methyl 4-(dimethyl(phenyl)silyl)-3-methyl-2-(picolinamido)butanoate (2n)



The compound **2n** was prepared according to the **GP-2** with starting materials **1n**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2n** was obtained as a colorless oil (19.7 mg, 53%, d.r. = 4:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.60 (d,  $J = 4.8$  Hz, 1H), 8.52 (d,  $J = 9.2$  Hz, 1H), 8.17 (d,  $J = 8.0$  Hz, 1H), 7.84 (t,  $J = 7.6$  Hz, 1H), 7.55 – 7.44 (m, 2H), 7.46 – 7.41 (m, 1H), 7.38 – 7.28 (m, 3H), 4.79 – 4.68 (m, 1H), 3.77 – 3.65 (m, 3H), 2.41 – 2.27 (m, 1H), 1.03 – 0.90 (m, 4H), 0.79 – 0.68 (m, 1H), 0.39 – 0.26 (m, 6H). **Major:**


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.24, 164.51, 149.61, 148.40, 138.94, 137.41, 133.66, 129.15, 127.96, 126.44, 122.47, 58.89, 52.22, 32.95, 19.62, 18.52, -2.09, -2.37. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.16, 164.44, 149.61, 148.40, 138.94, 137.41, 133.66, 129.06, 127.92, 126.44, 122.47, 58.89, 52.29, 32.95, 20.29, 18.11, -2.09, -2.37. **HRMS (ESI):** calcd. for  $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}_3\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 393.1604, found: 393.1595.

**(2S,3S)-methyl 4-((4-methoxyphenyl)dimethylsilyl)-3-methyl-2-(picolinamido)butanoate (2o)**




The compound **2o** was prepared according to the **GP-2** with starting materials **1o**, purified by column chromatography in hexane: ethyl acetate = 8:1. **2o** was obtained as a colorless oil (18 mg, 45%, d.r. = 3:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.66 – 8.57 (m, 1H), 8.52 (d,  $J$  = 9.2 Hz, 1H), 8.20 – 8.14 (m, 1H), 7.84 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.47 – 7.37 (m, 3H), 6.97 – 6.81 (m, 2H), 4.77 – 4.69 (m, 1H), 3.84 – 3.77 (m, 3H), 3.76 – 3.66 (m, 3H), 2.40 – 2.26 (m, 1H), 1.05 – 0.86 (m, 4H), 0.75 – 0.65 (m, 1H), 0.35 – 0.25 (m, 6H). **Major:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.28, 164.51, 160.53, 149.61, 148.40, 137.41, 135.11, 129.70, 126.45, 122.47, 113.74, 58.92, 55.15, 52.23, 32.97, 19.60, 18.73, -1.91, -2.14. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.19, 164.43, 160.46, 149.61, 148.40, 137.41, 135.11, 129.84, 126.45, 122.47, 113.70, 58.92, 55.11, 52.29, 32.97, 20.49, 18.11, -1.91, -2.14. **HRMS (ESI):** calcd. for  $\text{C}_{21}\text{H}_{28}\text{N}_2\text{O}_4\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 423.1700, found: 423.1706.

**(2S,3S)-methyl 3-methyl-2-(picolinamido)-4-(trimethylgermyl)butanoate (2p)**




The compound **2p** was prepared according to the **GP-2** with starting materials **1a** (0.2mmol), purified by column chromatography in hexane: ethyl acetate = 8:1. **2p** was obtained as a colorless oil (24.1mg, 34%, d.r. = 3:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.66 – 8.46 (m, 2H), 8.18 (d,  $J$  = 7.8 Hz, 1H), 7.84 (td,  $J$  = 8.0, 1.6 Hz, 1H), 7.50 – 7.36 (m, 1H), 4.82 – 4.69 (m, 1H), 3.76 (s, 3H), 2.42 – 2.24 (m, 1H), 1.04 – 0.98 (m, 3H), 0.96 – 0.79 (m, 1H), 0.75 – 0.65 (m, 1H), 0.22 – 0.07 (m, 9H). **Major:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.30, 164.45, 149.67, 148.41, 137.43, 126.45, 122.49, 58.89, 52.28, 34.12, 19.80, 19.27, -1.34. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.30, 164.45, 149.67, 148.41, 137.43, 126.45, 122.49, 58.82, 52.31, 34.09, 21.71, 17.83, -1.27. **HRMS (ESI):** calcd. for  $\text{C}_{15}\text{H}_{24}\text{N}_2\text{O}_3\text{GeNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 377.0891, found: 377.0893.

**N-(3-methyl-4-(trimethylsilyl)butan-2-yl)picolinamide (2q)**



The compound **2q** was prepared according to the **GP-2** with starting materials **1q** (0.2mmol), purified by column chromatography in hexane: ethyl acetate = 8:1. **2q** was obtained as a colorless oil (22.5 mg, 43%, d.r. = 1.4:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.54 (d,  $J$  = 4.4 Hz, 1H), 8.19 (d,  $J$  = 7.8 Hz, 1H), 8.09 – 7.91 (m, 1H), 7.83 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.46 – 7.34 (m, 1H), 4.16 – 3.99 (m, 1H), 1.97 – 1.82 (m, 1H), 1.22 – 1.14 (m, 3H), 1.04 – 0.92 (m, 3H), 0.80 – 0.61 (m, 1H), 0.47 – 0.35 (m, 1H), 0.10 – -0.05 (m, 9H). **Major:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  163.67, 150.39, 148.10, 137.42, 126.06, 122.33, 51.17, 34.45, 20.11, 18.52, 16.89, -0.64. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  163.67, 150.39, 148.10, 137.42, 126.06, 122.33, 51.33, 34.62, 20.39, 18.29, 17.51, -0.64. **HRMS (ESI):** calcd. for  $\text{C}_{14}\text{H}_{24}\text{N}_2\text{OSiH}$  ( $\text{M} + \text{H}$ ) $^+$ : 265.1731, found: 265.1732.


**N-(2-methyl-4-(trimethylsilyl)butan-2-yl)picolinamide (2r)**



The compound **2r** was prepared according to the **GP-2** with starting materials **1r** (0.2mmol), purified by column chromatography in hexane: ethyl acetate = 8:1. **2r** was obtained as a colorless oil (5.4 mg, 10%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.56 – 8.48 (m, 1H), 8.20 – 8.14 (m, 1H), 7.98 – 7.89 (m, 1H), 7.82 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.42 – 7.35 (m, 1H), 1.82 – 1.71 (m, 2H), 1.44 (s, 6H), 0.53 – 0.44 (m, 2H),


-0.01 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  163.32, 151.09, 147.90, 137.46, 125.91, 121.83, 54.41, 34.87, 26.37, 10.49, -1.69. HRMS (ESI): calcd. for  $\text{C}_{14}\text{H}_{24}\text{N}_2\text{OSiH}$  ( $\text{M} + \text{H}$ ) $^+$ : 265.1731, found: 265.1729.

**(S)-methyl 3-methyl-2-((2S,3S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)butanoate (4a)**




The compound **4a** was prepared according to the GP-2 with starting materials **3a**, purified by column chromatography in hexane: acetone = 4:1. **4a** was obtained as a colorless oil (16.9 mg, 42%, d.r. = 3:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.67 – 8.48 (m, 2H), 8.22 – 8.15 (m, 1H), 7.84 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.47 – 7.38 (m, 1H), 6.67 – 6.55 (m, 1H), 4.58 – 4.46 (m, 2H), 3.72 (s, 3H), 2.40 – 2.27 (m, 1H), 2.21 – 2.10 (m, 1H), 1.03 (d,  $J$  = 6.8, 3H), 0.88 (t,  $J$  = 6.6 Hz, 6H), 0.83 – 0.75 (m, 1H), 0.53 – 0.41 (m, 1H), 0.05 – 0 (m, 9H). Major:  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.29, 171.17, 164.78, 149.55, 148.48, 137.44, 126.50, 122.47, 60.29, 57.32, 52.22, 32.75, 31.29, 19.52, 19.43, 19.04, 17.96, -0.69. Minor:  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.27, 171.17, 164.75, 149.51, 148.48, 137.47, 126.53, 122.47, 60.61, 57.32, 52.22, 32.40, 31.29, 19.52, 19.43, 19.04, 18.11, -0.63. HRMS (ESI): calcd. for  $\text{C}_{20}\text{H}_{33}\text{N}_3\text{O}_4\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 430.2132, found: 430.2127.

**Methyl ((S)-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butan-oyl)-L-valinate (4a')**




The compound **4a'** was prepared according to the GP-2 with starting materials **3a**, purified by column chromatography in hexane: acetone = 4:1. **4a'** was obtained as a colorless oil (13 mg, 27%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.68 – 8.51 (m, 2H), 8.20 (dt,  $J$  = 8.0, 1.2 Hz, 1H), 7.87 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.50 – 7.43 (m, 1H), 6.55 (d,  $J$  = 9.2 Hz, 1H), 4.60 (dd,  $J$  = 8.7, 3.0 Hz, 1H), 4.44 (d,  $J$  = 9.2 Hz, 1H), 3.69 (s, 3H), 2.63 – 2.44 (m, 1H), 0.94 (s, 9H), 0.80 (dd,  $J$  = 14.4, 3.6 Hz, 1H), 0.74 (dd,  $J$  = 15.2, 10.0 Hz, 1H), 0.63 (dd,  $J$  = 14.4, 10.0 Hz, 1H), 0.53 (dd,  $J$  = 15.2, 4.0 Hz, 1H), 0.17 – 0 (m, 18H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.82, 170.90, 165.00, 149.59, 148.52, 137.56, 126.60, 122.53, 60.25, 58.87, 51.93, 34.88, 33.21, 26.71, 21.53, 20.96, -0.50, -0.56. HRMS (ESI): calcd. for  $\text{C}_{23}\text{H}_{41}\text{N}_3\text{O}_4\text{Si}_2\text{Na}$  ( $\text{M} + \text{Na}$ ) $^+$ : 502.2527, found: 502.2516.

**(S)-methyl 3,3-dimethyl-2-((2S,3S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)butanoate (4b)**




The compound **4b** was prepared according to the GP-2 with starting materials **3b**, purified by column chromatography in hexane: acetone = 4:1. **4b** was obtained as a colorless oil (16.4 mg, 39%, d.r. = 4:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.64 – 8.48 (m, 2H), 8.19 (dt,  $J$  = 8.0, 1.2 Hz, 1H), 7.85 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.48 – 7.40 (m, 1H), 6.68 – 6.55 (m, 1H), 4.54 – 4.48 (m, 1H), 4.47 – 4.41 (m, 1H), 3.75 – 3.68 (m, 3H), 2.40 – 2.28 (m, 1H), 1.02 (d,  $J$  = 6.8 Hz, 3H), 0.94 (s, 9H), 0.82 – 0.72 (m, 1H), 0.51 – 0.40 (m, 1H), 0.05 – 0 (m, 9H). Major:  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.87, 170.96, 164.84, 149.55, 148.50, 137.46, 126.52, 122.48, 60.29, 51.91, 34.76, 32.62, 26.69, 19.58, 19.39, -0.69. Minor:  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.87, 170.98, 164.84, 149.55, 148.50, 137.46, 126.56, 122.48, 60.73, 51.91, 34.76, 32.62, 26.69, 19.58, 19.39, -0.62. HRMS (ESI): calcd. for  $\text{C}_{21}\text{H}_{35}\text{N}_3\text{O}_4\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 444.2289, found: 444.2280.

**Methyl (S)-3,3-dimethyl-2-((S)-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanoyl)-L-alloisoleucinate (4b')**




The compound **4b'** was prepared according to the **GP-2** with starting materials **3b**, purified by column chromatography in hexane: acetone = 4:1. **4b'** was obtained as a colorless oil (7.1 mg, 15%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.68 – 8.51 (m, 2H), 8.20 (dt, *J* = 8.0, 1.2 Hz, 1H), 7.87 (td, *J* = 7.6, 1.6 Hz, 1H), 7.50 – 7.42 (m, 1H), 6.55 (d, *J* = 9.2 Hz, 1H), 4.60 (dd, *J* = 8.4, 3.0 Hz, 1H), 4.44 (d, *J* = 9.2 Hz, 1H), 3.69 (s, 3H), 2.61 – 2.50 (m, 1H), 0.94 (s, 9H), 0.80 (dd, *J* = 14.0, 3.6 Hz, 1H), 0.74 (dd, *J* = 15.2, 10.0 Hz, 1H), 0.63 (dd, *J* = 14.0, 10.0 Hz, 1H), 0.53 (dd, *J* = 15.2, 4.0 Hz, 1H), 0.10 – 0.03 (m, 18H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.82, 170.90, 165.00, 149.59, 148.52, 137.56, 126.60, 122.53, 60.25, 58.87, 51.93, 34.88, 33.21, 26.71, 21.53, 20.96, -0.50, -0.56. HRMS (ESI): calcd. for C<sub>24</sub>H<sub>43</sub>N<sub>3</sub>O<sub>4</sub>Si<sub>2</sub>Na (M + Na)<sup>+</sup>: 516.2684, found: 516.2665.

**(2S,3R)-methyl 3-methyl-2-((2S,3S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanoyl)-pentanoate (4c)**



The compound **4c** was prepared according to the **GP-2** with starting materials **3c**, purified by column chromatography in hexane: acetone = 4:1. **4c** was obtained as a colorless oil (16.0 mg, 38%, d.r. = 2.5:1), diastereomeric ratio was determined by <sup>1</sup>H NMR. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.67 – 8.44 (m, 2H), 8.18 (dt, *J* = 8.0, 1.2 Hz, 1H), 7.89 – 7.81 (m, 1H), 7.49 – 7.39 (m, 1H), 6.63 – 6.49 (m, 1H), 4.58 (dd, *J* = 8.4, 5.2 Hz, 1H), 4.53 – 4.42 (m, 1H), 3.72 (s, 3H), 2.41 – 2.25 (m, 1H), 1.96 – 1.82 (m, 2H), 1.45 – 1.33 (m, 1H), 1.21 – 1.08 (m, 1H), 1.06 – 0.99 (m, 3H), 0.90 – 0.83 (m, 6H), 0.82 – 0.74 (m, 1H), 0.51 – 0.41 (m, 1H), 0.03 – 0.01 (m, 9H). **Major:** <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.25, 170.98, 164.78, 149.54, 148.49, 137.45, 126.51, 122.47, 60.27, 56.62, 52.20, 37.94, 32.80, 25.33, 19.52, 19.39, 15.55, 11.65, -0.68. **Minor:** <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.22, 170.98, 164.78, 149.54, 148.48, 137.49, 126.54, 122.47, 60.60, 56.62, 52.20, 37.91, 32.80, 25.33, 21.31, 18.10, 15.55, 11.65, -0.62. HRMS (ESI): calcd. for C<sub>21</sub>H<sub>35</sub>N<sub>3</sub>O<sub>4</sub>SiNa (M + Na)<sup>+</sup>: 444.2289, found: 444.2280.

**Methyl ((S)-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanoyl)-L-alloisoleucinate (4c')**




The compound **4c'** was prepared according to the **GP-2** with starting materials **3c**, purified by column chromatography in hexane: acetone = 4:1. **4c'** was obtained as a colorless oil (7.8 mg, 16%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.69 – 8.53 (m, 2H), 8.20 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.86 (td, *J* = 7.6, 1.6 Hz, 1H), 7.50 – 7.38 (m, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 4.65 – 4.53 (m, 2H), 3.70 (s, 3H), 2.61 – 2.48 (m, 1H), 1.92 – 1.84 (m, 1H), 1.47 – 1.39 (m, 1H), 1.19 – 1.10 (m, 1H), 0.93 – 0.84 (m, 6H), 0.81 – 0.70 (m, 2H), 0.63 (dd, *J* = 14.0, 9.6 Hz, 1H), 0.53 (dd, *J* = 15.2, 4.0 Hz, 1H), 0.14 – -0.00 (m, 17H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.24, 170.84, 164.95, 149.58, 148.50, 137.55, 126.59, 122.52, 58.82, 56.62, 52.23, 38.11, 33.37, 25.38, 21.52, 20.90, 15.56, 11.66, -0.51, -0.57. HRMS (ESI): calcd. for C<sub>24</sub>H<sub>43</sub>N<sub>3</sub>O<sub>4</sub>Si<sub>2</sub>Na (M + Na)<sup>+</sup>: 516.2684, found: 516.2667.

**(S)-methyl 1-((2S,3S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanoyl)pyrrolidine-2-carboxylate (4d)**


The compound **4d** was prepared according to the **GP-2** with starting materials **3d**, purified by column






chromatography in hexane: acetone = 4:1. **4d** was obtained as a colorless oil (19.4 mg, 48%, d.r. = 2:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  **$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )**  $\delta$  8.68 – 8.50 (m, 2H), 8.12 (d,  $J$  = 7.6 Hz, 1H), 7.81 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.44 – 7.32 (m, 1H), 4.86 – 4.70 (m, 1H), 4.56 – 4.45 (m, 1H), 3.99 – 3.85 (m, 1H), 3.80 – 3.62 (m, 4H), 2.26 – 2.17 (m, 2H), 2.09 – 1.92 (m, 3H), 1.16 – 1.00 (m, 3H), 0.99 – 0.84 (m, 1H), 0.57 – 0.35 (m, 1H), 0.06 – -0.06 (m, 9H). **Major:**  **$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )**  $\delta$  172.53, 170.83, 164.49, 149.67, 148.46, 137.26, 126.29, 122.28, 59.01, 57.45, 52.24, 47.50, 33.46, 29.20, 25.15, 19.29, 19.19, -0.57. **Minor:**  **$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )**  $\delta$  172.53, 170.63, 164.40, 149.72, 148.42, 137.26, 126.29, 122.28, 59.01, 57.55, 52.24, 47.43, 33.02, 29.20, 25.15, 21.13, 17.72, -0.59. **HRMS (ESI):** calcd. for  $\text{C}_{20}\text{H}_{31}\text{N}_3\text{O}_4\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 428.1976, found: 428.1984.

**Methyl ((S)-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butano-yl)-L-prolinate (4d')**



The compound **4d'** was prepared according to the **GP-2** with starting materials **3d**, purified by column chromatography in hexane: acetone = 4:1. **4d'** was obtained as a colorless oil (3.4 mg, 7%).  **$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )**  $\delta$  8.71 – 8.50 (m, 2H), 8.14 (dt,  $J$  = 8.0, 1.2 Hz, 1H), 7.81 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.44 – 7.37 (m, 1H), 4.89 (dd,  $J$  = 9.6, 4.4 Hz, 1H), 4.51 (dd,  $J$  = 8.4, 5.6 Hz, 1H), 3.96 – 3.81 (m, 1H), 3.76 – 3.62 (m, 4H), 2.44 – 2.30 (m, 1H), 2.26 – 2.19 (m, 1H), 2.15 – 2.06 (m, 1H), 2.02 – 1.89 (m, 2H), 1.01 – 0.88 (m, 2H), 0.69 – 0.54 (m, 2H), 0.14 – 0.04 (m, 18H).  **$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )**  $\delta$  172.56, 170.74, 164.76, 149.95, 148.49, 137.27, 126.26, 122.28, 59.25, 56.22, 52.23, 47.43, 33.25, 29.07, 25.50, 21.56, 19.67, -0.18, -0.27. **HRMS (ESI):** calcd. for  $\text{C}_{23}\text{H}_{39}\text{N}_3\text{O}_4\text{Si}_2\text{Na}$  ( $\text{M} + \text{Na}$ ) $^+$ : 500.2371, found: 500.2380.


**(S)-methyl 4-methyl-2-((2S,3S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)pentanoate (4e)**



The compound **4e** was prepared according to the **GP-2** with starting materials **3e**, purified by column chromatography in hexane: acetone = 4:1. **4e** was obtained as a colorless oil (12.3 mg, 30%, d.r. = 3.5:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  **$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )**  $\delta$  8.63 – 8.49 (m, 2H), 8.18 (dt,  $J$  = 8.0, 1.2 Hz, 1H), 7.85 (td,  $J$  = 7.8, 1.6 Hz, 1H), 7.47 – 7.41 (m, 1H), 6.48 – 6.37 (m, 1H), 4.67 – 4.58 (m, 1H), 4.54 – 4.42 (m, 1H), 3.72 (s, 3H), 2.39 – 2.26 (m, 1H), 1.67 – 1.48 (m, 3H), 1.03 (d,  $J$  = 6.8 Hz, 3H), 0.93 – 0.83 (m, 6H), 0.81 – 0.73 (m, 1H), 0.55 – 0.42 (m, 1H), 0.05 – 0.01 (m, 9H). **Major:**  **$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )**  $\delta$  173.28, 170.96, 164.79, 149.56, 148.50, 137.46, 126.53, 122.48, 60.23, 52.39, 50.92, 41.64, 32.80, 24.96, 22.85, 22.06, 19.47, 19.38, -0.66. **Minor:**  **$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )**  $\delta$  173.28, 170.96, 164.76, 149.56, 148.48, 137.48, 126.53, 122.48, 60.23, 52.39, 50.94, 41.64, 32.80, 24.96, 22.82, 22.06, 21.29, 18.06, -0.61. **HRMS (ESI):** calcd. for  $\text{C}_{21}\text{H}_{35}\text{N}_3\text{O}_4\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 444.2289, found: 444.2286.

**(S)-methyl 2-cyclohexyl-2-((2S,3S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)acetate (4f)**

The compound **4f** was prepared according to the **GP-2** with starting materials **3f**, purified by column chromatography in hexane: acetone = 4:1. **4f** was obtained as a colorless oil (12.3 mg, 30%, d.r. = 3:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  **$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )**  $\delta$  8.67 – 8.48 (m, 2H),




8.18 (dt,  $J = 7.8, 1.2$  Hz, 1H), 7.85 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.48 – 7.39 (m, 1H), 6.59 – 6.45 (m, 1H), 4.61 – 4.43 (m, 2H), 3.71 (s, 3H), 2.42 – 2.25 (m, 1H), 1.81 – 1.74 (m, 1H), 1.70 – 1.51 (m, 5H), 1.20 – 1.11 (m, 2H), 1.08 – 0.92 (m, 6H), 0.84 – 0.74 (m, 1H), 0.51 – 0.41 (m, 1H), 0.06 – -0.01 (m, 9H).

**Major:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.28, 171.00, 164.81, 149.58, 148.49, 137.45, 126.51, 122.47, 60.27, 57.03, 52.22, 41.01, 32.79, 29.56, 28.40, 26.03, 19.55, 19.38, -0.68. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.28, 171.00, 164.76, 149.58, 148.49, 137.47, 126.53, 122.47, 60.62,

57.03, 52.22, 40.99, 32.43, 29.41, 28.37, 26.03, 21.34, 18.14, -0.62. **HRMS (ESI):** calcd. for  $\text{C}_{23}\text{H}_{37}\text{N}_3\text{O}_4\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 470.2445, found: 470.2424.

### Methyl ((S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butanoyl)-L-valinate (4g)




The compound **4g** was prepared according to the **GP-2** with starting materials **3g**, purified by column chromatography in hexane: acetone = 6:1.

**4g** was obtained as a colorless oil (19.6 mg, 47%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.76 (d,  $J = 9.6$  Hz, 1H), 8.62 – 8.54 (m, 1H), 8.21 (dd,  $J = 8.0, 1.2$  Hz, 1H), 7.83 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.46 – 7.38 (m, 1H), 6.72 (d,  $J = 8.4$  Hz, 1H), 4.59 – 4.49 (m, 2H), 3.73 (s, 3H), 2.16 – 2.05 (m, 1H), 1.14 (d,  $J = 9.6$  Hz, 6H), 0.99 (d,  $J = 14.5$  Hz, 1H), 0.90 – 0.78 (m, 7H), 0.04 (s, 9H).

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.33, 170.71, 164.37, 149.65, 148.49, 137.36, 126.38, 122.49, 62.96, 57.26, 52.16, 38.06, 31.21, 27.78, 26.55, 26.53, 19.03, 17.99, 1.10. **HRMS (ESI):** calcd. for  $\text{C}_{21}\text{H}_{35}\text{N}_3\text{O}_4\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 444.2289, found: 444.2280.

### Methyl ((S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanoyl)-L-valinate (4g')




The compound **4g'** was prepared according to the **GP-2** with starting materials **3g**, purified by column chromatography in hexane: acetone = 6:1.

**4g'** was obtained as a colorless oil (8.2 mg, 17%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.68 (d,  $J = 9.2$  Hz, 1H), 8.64 – 8.54 (m, 1H), 8.16 (d,  $J = 8.0$  Hz, 1H), 7.90 – 7.78 (m, 1H), 7.44 (dd,  $J = 7.6, 4.8$  Hz, 1H), 6.34 (d,  $J = 8.4$  Hz, 1H), 4.56 – 4.43 (m, 2H), 3.72 (s, 3H), 2.21 – 2.07 (m, 1H), 1.34 – 1.25 (m, 2H), 1.21 (s, 3H), 1.02 – 0.94 (m, 2H), 0.88 (d,  $J = 6.9$  Hz,

6H), 0.18 – 0.04 (m, 18H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.24, 170.56, 164.63, 149.64, 148.53, 137.46, 126.46, 122.38, 62.28, 57.24, 52.21, 40.38, 31.37, 29.42, 28.90, 27.77, 19.02, 17.98, 1.29, 1.20.

**HRMS (ESI):** calcd. for  $\text{C}_{24}\text{H}_{43}\text{N}_3\text{O}_4\text{Si}_2\text{Na}$  ( $\text{M} + \text{Na}$ ) $^+$ : 516.2684, found: 516.2665.

### Methyl((S)-2-((S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)-3,3-dimethylbutanoate (4h)




The compound **4h** was prepared according to the **GP-2** with starting materials **3h**, purified by column chromatography in hexane: acetone = 6:1.

**4h** was obtained as a colorless oil (20.6 mg, 48%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.75 (d,  $J = 10.0$  Hz, 1H), 8.64 – 8.53 (m, 1H), 8.23 (dd,  $J = 8.0, 1.2$  Hz, 1H), 7.83 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.46 – 7.37 (m, 1H), 6.70 (d,  $J = 9.0$  Hz, 1H), 4.56 (d,  $J = 10.0$  Hz, 1H), 4.43 (d,  $J = 9.0$  Hz, 1H), 3.72 (s, 3H), 1.13 (s, 3H), 1.11 (s, 3H), 0.98 (d,  $J = 14.8$  Hz, 1H), 0.92 (s, 9H), 0.79 (d,  $J = 14.4$  Hz, 1H), 0.03 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz, Chloroform- $d$ )  $\delta$  171.86, 170.61, 164.38, 149.65,

148.47, 137.36, 126.36, 122.53, 62.91, 60.26, 51.82, 38.07, 34.61, 27.90, 26.69, 26.59, 26.37, 1.07.

**HRMS (ESI):** calcd. for  $C_{22}H_{37}N_3O_4SiNa$  ( $M + Na$ )<sup>+</sup>: 458.2445, found: 458.2429.


**Methyl(S)-3,3-dimethyl-2-((S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanamido)butanoate (4h')**



The compound **4h'** was prepared according to the **GP-2** with starting materials **3h**, purified by column chromatography in hexane: acetone = 6:1. **4h'** was obtained as a colorless oil (8.6 mg, 17%). **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.78 – 8.63 (m, 1H), 8.60 (d,  $J = 4.8$  Hz, 1H), 8.21 – 8.09 (m, 1H), 7.92 – 7.77 (m, 1H), 7.49 – 7.35 (m, 1H), 6.41 (d,  $J = 9.2$  Hz, 1H), 4.48 (dd,  $J = 9.2, 1.6$  Hz, 1H), 4.42 (dd,  $J = 9.2, 1.6$  Hz, 1H), 3.78 – 3.64 (m, 3H), 1.29 (d,  $J = 14.8$  Hz, 2H), 1.20 (s, 3H), 1.03 (d,  $J = 14.8$  Hz,

2H), 0.93 (s, 9H), 0.17 – 0.03 (m, 18H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 171.79, 170.45, 164.65, 149.62, 148.53, 137.46, 126.47, 122.37, 62.24, 60.21, 51.87, 40.37, 34.76, 29.41, 28.97, 27.77, 26.70, 1.27, 1.20. **HRMS (ESI):** calcd. for  $C_{25}H_{45}N_3O_4Si_2Na$  ( $M + Na$ )<sup>+</sup>: 530.2841, found: 530.2829.


**Methyl((S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butanoyl)-L-alloisoleucinate (4i)**



The compound **4i** was prepared according to the **GP-2** with starting materials **3i**, purified by column chromatography in hexane: acetone = 4:1. **4i** was obtained as a colorless oil (15.4 mg, 36%). **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.76 (d,  $J = 9.6$  Hz, 1H), 8.59 (d,  $J = 4.4$  Hz, 1H), 8.24 – 8.14 (m, 1H), 7.83 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.46 – 7.37 (m, 1H), 6.73 – 6.52 (m, 1H), 4.57 (dd,  $J = 8.4, 4.8$  Hz, 1H), 4.50 (td,  $J = 9.6, 4.4$  Hz, 1H), 3.73 (s, 3H), 1.91 – 1.77 (m, 1H), 1.44 – 1.32 (m, 1H), 1.19 – 1.05 (m, 7H), 0.98 (d,  $J =$

14.4 Hz, 1H), 0.88 – 0.77 (m, 7H), 0.04 (s, 9H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 172.26, 170.52, 164.37, 149.65, 148.50, 137.36, 126.38, 122.48, 62.97, 56.53, 52.12, 38.11, 37.86, 27.78, 26.54, 25.35, 15.56, 11.66, 1.10. **HRMS (ESI):** calcd. for  $C_{22}H_{37}N_3O_4SiNa$  ( $M + Na$ )<sup>+</sup>: 458.2445, found: 458.2434.

**Methyl ((S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanoyl)-L-alloisoleucinate (4i')**




The compound **4i'** was prepared according to the **GP-2** with starting materials **3i**, purified by column chromatography in hexane: acetone = 4:1. **4i'** was obtained as a colorless oil (5.1 mg, 10%). **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.70 – 8.56 (m, 1H), 8.55 – 8.46 (m, 1H), 8.08 (dt,  $J = 8.0, 1.2$  Hz, 1H), 7.76 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.39 – 7.29 (m, 1H), 6.26 (d,  $J = 8.4$  Hz, 1H), 4.49 (dd,  $J = 8.4, 4.8$  Hz, 1H), 4.39 (d,  $J = 9.2$  Hz, 1H), 3.63 (s, 3H), 1.85 – 1.73 (m, 1H), 1.37 – 1.26 (m, 1H), 1.21 (d,  $J = 14.8$  Hz,

2H), 1.12 (s, 3H), 1.09 – 1.04 (m, 1H), 0.93 (d,  $J = 14.8$  Hz, 1H), 0.87 (d,  $J = 11.4$  Hz, 1H), 0.81 – 0.74 (m, 6H), 0.14 – -0.07 (m, 18H). **<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 172.21, 170.41, 164.62, 149.65, 148.53, 137.46, 126.46, 122.38, 62.24, 56.55, 52.16, 40.44, 38.00, 29.40, 28.87, 27.76, 25.37, 15.55, 11.69, 1.29, 1.21. **HRMS (ESI):** calcd. for  $C_{25}H_{45}N_3O_4Si_2Na$  ( $M + Na$ )<sup>+</sup>: 530.2841, found: 530.2832.


**Methyl(S)-2-cyclohexyl-2-((S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)acetate (4j)**

The compound **4j** was prepared according to the **GP-2** with starting materials **3j**, purified by column chromatography in hexane: acetone = 4:1. **4j** was obtained as a colorless oil (16.9 mg, 37%). **<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.76 (d,  $J = 10.0$  Hz, 1H), 8.63 – 8.52 (m, 1H), 8.19 (dd,  $J = 7.6, 1.2$  Hz, 1H),



7.83 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.46 – 7.36 (m, 1H), 6.58 (d,  $J = 8.4$  Hz, 1H), 4.55 – 4.41 (m, 2H), 3.72 (s, 3H), 1.78 – 1.52 (m, 6H), 1.17 – 0.93 (m, 12H), 0.82 (d,  $J = 14.4$  Hz, 1H), 0.04 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.30, 170.53, 164.38, 149.67, 148.50, 137.35, 126.38, 122.46, 62.95, 57.09, 52.13, 40.79, 38.16, 29.47, 28.51, 27.78, 26.58, 26.54, 25.99, 25.94, 1.10. HRMS (ESI): calcd. for  $\text{C}_{24}\text{H}_{39}\text{N}_3\text{O}_4\text{SiNa}$  ( $M + \text{Na}$ ) $^+$ : 484.2602, found: 484.2597.


**Methyl (S)-2-cyclohexyl-2-((S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)-3-((t-rimethylsilyl)-methyl)butanamido)acetate (4j')**



The compound **4j'** was prepared according to the **GP-2** with starting materials **3j**, purified by column chromatography in hexane: acetone = 4:1. **4j'** was obtained as a colorless oil (6.5 mg, 13%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.76 – 8.64 (m, 1H), 8.63 – 8.56 (m, 1H), 8.17 (d,  $J = 7.6$  Hz, 1H), 7.85 (td,  $J = 7.6, 2.0$  Hz, 1H), 7.48 – 7.40 (m, 1H), 6.34 (d,  $J = 8.6$  Hz, 1H), 4.59 – 4.45 (m, 2H), 3.74 – 3.68 (m, 3H), 1.82 – 1.74 (m, 1H), 1.66 – 1.47 (m, 5H), 1.34 – 1.28 (m, 2H), 1.21 (s, 3H), 1.17 – 1.12 (m, 2H), 1.03 – 0.89 (m, 5H), 0.17 – 0.03 (m, 18H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.22, 170.44, 164.65, 148.54, 137.46, 126.47, 122.38, 62.26, 56.92, 52.18, 41.12, 40.40, 29.56, 29.45, 28.39, 27.79, 26.05, 26.03, 1.30, 1.21. HRMS (ESI): calcd. for  $\text{C}_{27}\text{H}_{47}\text{N}_3\text{O}_4\text{Si}_2\text{Na}$  ( $M + \text{Na}$ ) $^+$ : 556.2997, found: 556.2980.


**4j'** was obtained as a colorless oil (6.5 mg, 13%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.76 – 8.64 (m, 1H), 8.63 – 8.56 (m, 1H), 8.17 (d,  $J = 7.6$  Hz, 1H), 7.85 (td,  $J = 7.6, 2.0$  Hz, 1H), 7.48 – 7.40 (m, 1H), 6.34 (d,  $J = 8.6$  Hz, 1H), 4.59 – 4.45 (m, 2H), 3.74 – 3.68 (m, 3H), 1.82 – 1.74 (m, 1H), 1.66 – 1.47 (m, 5H), 1.34 – 1.28 (m, 2H), 1.21 (s, 3H), 1.17 – 1.12 (m, 2H), 1.03 – 0.89 (m, 5H), 0.17 – 0.03 (m, 18H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.22, 170.44, 164.65, 148.54, 137.46, 126.47, 122.38, 62.26, 56.92, 52.18, 41.12, 40.40, 29.56, 29.45, 28.39, 27.79, 26.05, 26.03, 1.30, 1.21. HRMS (ESI): calcd. for  $\text{C}_{27}\text{H}_{47}\text{N}_3\text{O}_4\text{Si}_2\text{Na}$  ( $M + \text{Na}$ ) $^+$ : 556.2997, found: 556.2980.

**Methyl((S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butanoyl)-L-leucinate (4k)**



The compound **4k** was prepared according to the **GP-2** with starting materials **3k**, purified by column chromatography in hexane: acetone = 4:1. **4k** was obtained as a colorless oil (15.1 mg, 42%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.76 (d,  $J = 10.0$  Hz, 1H), 8.66 – 8.54 (m, 1H), 8.18 (dt,  $J = 8.0, 1.2$  Hz, 1H), 7.83 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.45 – 7.39 (m, 1H), 6.67 (d,  $J = 8.0$  Hz, 1H), 4.63 – 4.56 (m, 1H), 4.50 (d,  $J = 10.0$  Hz, 1H), 3.72 (s, 3H), 1.65 – 1.54 (m, 2H), 1.52 – 1.43 (m, 1H), 1.14 (d,  $J = 10.0$  Hz, 6H), 0.98 (d,  $J = 14.8$  Hz, 1H), 0.86 – 0.79 (m, 7H), 0.04 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  173.33, 170.44, 164.35, 149.65, 148.52, 137.37, 126.40, 122.45, 62.85, 52.27, 50.87, 41.46, 38.20, 27.67, 26.55, 26.49, 24.88, 22.70, 22.11, 1.12. HRMS (ESI): calcd. for  $\text{C}_{22}\text{H}_{37}\text{N}_3\text{O}_4\text{SiNa}$  ( $M + \text{Na}$ ) $^+$ : 458.2445, found: 458.2434.


**Methyl (S)-3,3-dimethyl-2-((S)-2-(picolinamido)-4-(trimethylsilyl)butanamido)butanoate (4l)**



The compound **4l** was prepared according to the **GP-2** with starting materials **3l**, purified by column chromatography in hexane: acetone = 4:1. **4l** was obtained as a colorless oil (16.1 mg, 40%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.61 – 8.54 (m, 1H), 8.46 (d,  $J = 8.4$  Hz, 1H), 8.23 – 8.13 (m, 1H), 7.89 – 7.80 (m, 1H), 7.49 – 7.37 (m, 1H), 6.83 (d,  $J = 9.2$  Hz, 1H), 4.64 – 4.53 (m, 1H), 4.44 (d,  $J = 9.2$  Hz, 1H), 3.71 (s, 3H), 2.04 – 1.93 (m, 1H), 1.82 – 1.70 (m, 1H), 0.93 (s, 9H), 0.60 – 0.50 (m, 2H), -0.02 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.82, 171.26, 164.70, 149.43, 148.47, 137.49, 126.56, 122.42, 60.30, 55.95, 51.91, 34.80, 26.63, 26.60, 12.37, -1.76. HRMS (ESI): calcd. for

$C_{20}H_{33}N_3O_4SiNa$  ( $M + Na$ )<sup>+</sup>: 430.2133, found: 430.2128.


**Methyl((2S,3S)-3-methoxy-2-(picolinamido)-4-(trimethylsilyl)butanoyl)-L-proline (4m)**



The compound **4m** was prepared according to the **GP-2** with starting materials **3m**, purified by column chromatography in hexane: acetone = 4:1. **4m** was obtained as a colorless oil (18.7mg, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.92 – 8.75 (m, 1H), 8.61 – 8.49 (m, 1H), 8.15 – 8.07 (m, 1H), 7.85 – 7.76 (m, 1H), 7.43 – 7.34 (m, 1H), 5.06 – 4.89 (m, 1H), 4.53 (dd, *J* = 8.4, 5.2 Hz, 1H), 3.86 – 3.63 (m, 6H), 3.53 – 3.44 (m, 3H), 2.26 – 2.14 (m, 1H), 2.12 – 2.02 (m, 1H), 2.00 – 1.93 (m, 2H), 1.04 – 0.96 (m, 1H), 0.96 – 0.89 (m, 1H), 0.07 – -0.03 (m, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.42, 169.25, 164.31, 149.63, 148.54,

137.22, 126.32, 122.16, 80.42, 59.34, 57.75, 55.29, 52.20, 47.51, 29.10, 25.30, 19.76, -0.76. HRMS (ESI): calcd. for  $C_{20}H_{31}N_3O_5SiNa$  ( $M + Na$ )<sup>+</sup>: 444.1925, found: 444.1911.


**Methyl(S)-2-((2S,3S)-3-methoxy-2-(picolinamido)-4-(trimethylsilyl)butanamido)-3,3-dimethylbutanoate (4n)**



The compound **4n** was prepared according to the **GP-2** with starting materials **3n**, purified by column chromatography in hexane: acetone = 4:1. **4n** was obtained as a colorless oil (14.2mg, 33%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.96 – 8.79 (m, 1H), 8.64 – 8.56 (m, 1H), 8.15 (dt, *J* = 7.6, 1.2 Hz, 1H), 7.84 (td, *J* = 7.6, 1.6 Hz, 1H), 7.47 – 7.41 (m, 1H), 7.38 (d, *J* = 8.8 Hz, 1H), 4.89 – 4.77 (m, 1H), 4.47 – 4.32 (m, 1H), 3.98 – 3.90 (m, 1H), 3.71 (s, 3H), 3.60 (s, 3H), 0.99 (s, 9H), 0.91 (dd, *J* = 14.7, 10.5 Hz,

1H), 0.73 (dd, *J* = 14.7, 4.6 Hz, 1H), 0.06 – -0.02 (m, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.52, 169.82, 164.76, 149.57, 148.64, 137.38, 126.52, 122.22, 79.11, 60.87, 57.34, 54.87, 51.80, 34.31, 26.75, 17.59, -0.84. HRMS (ESI): calcd. for  $C_{21}H_{35}N_3O_5SiNa$  ( $M + Na$ )<sup>+</sup>: 460.2238, found: 460.2225.


**Methyl (S)-3,3-dimethyl-2-((2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)p-entanamido)butanoate (4o)**



The compound **4o** was prepared according to the **GP-2** with starting materials **3o**, purified by column chromatography in hexane: acetone = 4:1. **4o** was obtained as a colorless oil (21.2mg, 33%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.62 – 8.53 (m, 1H), 8.50 (d, *J* = 9.2 Hz, 1H), 8.18 (dt, *J* = 8.0, 1.2 Hz, 1H), 7.85 (td, *J* = 7.6, 1.6 Hz, 1H), 7.50 – 7.39 (m, 1H), 6.60 (d, *J* = 9.2 Hz, 1H), 4.53 (dd, *J* = 9.2, 6.8 Hz, 1H), 4.43 (d, *J* = 9.2 Hz, 1H), 3.70 (s, 3H), 2.34 – 2.17 (m, 1H), 1.57 – 1.41 (m, 2H), 1.02 – 0.85 (m, 12H), 0.64 –

0.55 (m, 2H), 0.02 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.80, 171.06, 164.62, 149.44, 148.47, 137.50, 126.55, 122.42, 60.26, 57.79, 51.92, 37.32, 34.79, 26.66, 24.63, 17.36, 10.43, -0.71. HRMS (ESI): calcd. for  $C_{22}H_{37}N_3O_4SiNa$  ( $M + Na$ )<sup>+</sup>: 458.2445, found: 458.2429.


**(S)-methyl 2-((S)-3,3-dimethyl-2-((2S,3S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)butanamido)-3,3-dimethylbutanoate (6a)**



The compound **6a** was prepared according to the **GP-2** with starting materials **5a**, purified by column chromatography in hexane: acetone = 4:1. **6a** was obtained as a colorless oil (24.6 mg, 46%, d.r. = 4:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.67 – 8.49 (m, 2H), 8.19 (d,  $J$  = 7.6 Hz, 1H), 7.91 – 7.77 (m, 1H), 7.42 (dd,  $J$  = 7.6, 4.8 Hz, 1H), 6.76 (d,  $J$  = 9.2 Hz, 1H), 6.45 – 6.30 (m, 1H), 4.55 – 4.44 (m, 1H), 4.43 – 4.36 (m, 1H), 4.35 –

4.27 (m, 1H), 3.71 (s, 3H), 2.41 – 2.23 (m, 1H), 1.04 – 0.90 (m, 21H), 0.78 (d,  $J$  = 14.4 Hz, 1H), 0.49 – 0.37 (m, 1H), 0.04 – -0.04 (m, 9H). **Major:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.77, 171.09, 170.19, 164.70, 149.59, 148.43, 137.43, 126.46, 122.54, 60.84, 60.53, 60.29, 51.91, 34.93, 34.74, 32.74, 26.73, 26.68, 19.65, 19.37, -0.65. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.77, 171.09, 170.19, 164.70, 149.55, 148.43, 137.46, 126.49, 122.54, 60.98, 60.77, 60.19, 51.91, 34.88, 34.86, 32.74, 26.73, 26.68, 21.23, 18.13, -0.61. **HRMS (ESI):** calcd. for  $\text{C}_{27}\text{H}_{46}\text{N}_4\text{O}_5\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 557.3129, found: 557.3109.


**Methyl (S)-2-((S)-3,3-dimethyl-2-((S)-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanamido)butanamido)-3,3-dimethylbutanoate (6a')**



The compound **6a'** was prepared according to the **GP-2** with starting materials **5a**, purified by column chromatography in hexane: acetone = 4:1. **6a'** was obtained as a colorless oil (11.6 mg, 19%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.70 – 8.49 (m, 2H), 8.17 (d,  $J$  = 7.6 Hz, 1H), 7.93 – 7.78 (m, 1H), 7.45 (dd,  $J$  = 7.6, 4.8 Hz, 1H), 6.70 (d,  $J$  = 8.8 Hz, 1H), 6.22 (d,  $J$  = 8.8 Hz, 1H), 4.59 (dd,  $J$  = 8.4, 3.2 Hz, 1H), 4.36 (d,  $J$  = 8.8 Hz, 1H), 4.25 (d,  $J$  = 8.8 Hz,

1H), 3.70 (s, 3H), 2.59 – 2.47 (m, 1H), 1.06 – 0.89 (m, 18H), 0.80 (dd,  $J$  = 14.4, 4.4 Hz, 1H), 0.73 (dd,  $J$  = 15.2 9.2 Hz, 1H), 0.64 (dd,  $J$  = 14.4, 9.2 Hz, 1H), 0.50 (dd,  $J$  = 15.4, 4.4 Hz, 1H), 0.18 – -0.02 (m, 18H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.75, 170.96, 170.12, 164.87, 149.56, 148.48, 137.51, 126.57, 122.50, 61.01, 60.34, 58.97, 51.92, 34.98, 34.70, 33.35, 26.74, 21.47, 21.13, -0.43, -0.60. **HRMS (ESI):** calcd. for  $\text{C}_{30}\text{H}_{54}\text{N}_4\text{O}_5\text{Si}_2\text{Na}$  ( $\text{M} + \text{Na}$ ) $^+$ : 629.3525, found: 629.3516.

**Methyl((S)-2-((S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)-3,3-dimethylbutanoyl)-L-valinate (6b)**




The compound **6b** was prepared according to the **GP-2** with starting materials **5b**, purified by column chromatography in hexane: acetone = 4:1. **6b** was obtained as a colorless oil (18.3 mg, 34%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.72 (d,  $J$  = 9.6 Hz, 1H), 8.64 – 8.52 (m, 1H), 8.27 – 8.15 (m, 1H), 7.82 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.47 – 7.37 (m, 1H), 6.66 (d,  $J$  = 9.2 Hz, 1H), 6.27 (d,  $J$  = 8.8 Hz, 1H), 4.55 (dd,  $J$  = 8.8, 5.2 Hz, 1H), 4.47 (d,  $J$  = 9.6 Hz, 1H), 4.27 (d,  $J$  = 9.2 Hz, 1H),

3.73 (s, 3H), 2.24 – 2.13 (m, 1H), 1.16 – 1.05 (m, 6H), 0.99 – 0.85 (m, 16H), 0.78 (d,  $J$  = 14.4 Hz, 1H), 0.02 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.28, 170.60, 170.30, 164.34, 149.68, 148.43, 137.40, 126.35, 122.59, 63.17, 60.97, 57.12, 52.29, 38.15, 34.79, 31.32, 27.73, 26.67, 26.65, 19.14, 17.86, 1.08. **HRMS (ESI):** calcd. for  $\text{C}_{27}\text{H}_{46}\text{N}_4\text{O}_5\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 557.3129, found: 557.3116.

**Methyl((S)-3,3-dimethyl-2-((S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanamido)butanoyl)-L-valinate (6b')**

The compound **6b'** was prepared according to the **GP-2** with starting materials **5b**, purified by column chromatography in hexane: acetone = 4:1. **6b'** was obtained as a colorless oil (5.2 mg, 9%).  $^1\text{H}$  NMR




(**400 MHz, CDCl<sub>3</sub>**)  $\delta$  8.66 (d,  $J$  = 8.8 Hz, 1H), 8.63 – 8.57 (m, 1H), 8.15 (dd,  $J$  = 7.6, 1.2 Hz, 1H), 7.84 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.49 – 7.38 (m, 1H), 6.51 (d,  $J$  = 8.8 Hz, 1H), 6.11 (d,  $J$  = 9.2 Hz, 1H), 4.53 (dd,  $J$  = 8.8, 4.8 Hz, 1H), 4.47 (d,  $J$  = 8.8 Hz, 1H), 4.24 (d,  $J$  = 9.2 Hz, 1H), 3.73 (s, 3H), 2.24 – 2.13 (m, 1H), 1.19 (s, 3H), 1.04 – 0.81 (m, 19H), 0.16 – 0.04 (m, 18H). <sup>13</sup>C

**NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$  172.22, 170.59, 170.30, 164.57,

149.71, 148.51, 137.43, 126.43, 122.40, 62.60, 61.06, 57.15, 52.30, 40.52, 34.94, 31.33, 29.67, 29.42, 28.99, 27.83, 26.72, 19.20, 17.82, 1.27, 1.16. **HRMS (ESI)**: calcd. for C<sub>30</sub>H<sub>54</sub>N<sub>4</sub>O<sub>5</sub>Si<sub>2</sub>Na (M + Na)<sup>+</sup>: 629.3525, found: 629.3512.


**Methyl (S)-2-((S)-2-((S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)-3,3-dimethylbutanoate (6c)**



The compound **6c** was prepared according to the **GP-2** with starting materials **5c**, purified by column chromatography in hexane: acetone = 4:1. **6c** was obtained as a colorless oil (18.4 mg, 34%). <sup>1</sup>H **NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$  8.72 (d,  $J$  = 9.6 Hz, 1H), 8.62 – 8.53 (m, 1H), 8.26 – 8.15 (m, 1H), 7.82 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.48 – 7.36 (m, 1H), 6.64 (d,  $J$  = 9.2 Hz, 1H), 6.26 (d,  $J$  = 9.2 Hz, 1H), 4.45 (dd,  $J$  = 9.2, 8.0 Hz, 2H), 4.26 (d,  $J$  = 9.2 Hz, 1H), 3.71 (s, 3H), 1.10 (d,  $J$  =

10.0 Hz, 6H), 0.98 – 0.89 (m, 19H), 0.78 (d,  $J$  = 14.4 Hz, 1H), 0.02 (s, 9H). <sup>13</sup>C **NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$  171.79, 170.60, 170.09, 164.33, 149.69, 148.43, 137.38, 126.34, 122.58, 63.16, 61.00, 60.10, 51.95, 38.11, 34.91, 34.87, 27.66, 26.73, 26.67, 1.10. **HRMS (ESI)**: calcd. for C<sub>28</sub>H<sub>48</sub>N<sub>4</sub>O<sub>5</sub>SiNa (M + Na)<sup>+</sup>: 571.3286, found: 571.3266.


**Methyl (S)-2-((S)-3,3-dimethyl-2-((S)-3-methyl-2-(picolinamido)-4-(trimethylsilyl)-3-((trimethylsilyl)methyl)butanamido)butanamido)-3,3-dimethylbutanoate (6c')**



The compound **6c'** was prepared according to the **GP-2** with starting materials **5c**, purified by column chromatography in hexane: acetone = 4:1. **6c'** was obtained as a colorless oil (5.7 mg, 9%). <sup>1</sup>H **NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$  8.66 (d,  $J$  = 8.8 Hz, 1H), 8.61 (dt,  $J$  = 4.8, 1.2 Hz, 1H), 8.14 (d,  $J$  = 7.6 Hz, 1H), 7.83 (td,  $J$  = 7.6, 1.6 Hz, 1H), 7.46 – 7.39 (m, 1H), 6.50 (d,  $J$  = 8.8 Hz, 1H), 6.16 (d,  $J$  = 9.2 Hz, 1H), 4.47 (d,  $J$  = 8.8 Hz, 1H), 4.42 (d,  $J$  = 9.2 Hz, 1H),

4.24 (d,  $J$  = 8.8 Hz, 1H), 3.72 (s, 3H), 1.18 (s, 3H), 1.04 – 0.84 (m, 22H), 0.15 – 0.02 (m, 18H). <sup>13</sup>C **NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$  171.76, 170.58, 170.08, 164.53, 149.71, 148.50, 137.42, 126.42, 122.40, 62.55, 61.07, 60.12, 51.96, 40.52, 35.06, 34.91, 29.67, 29.42, 28.93, 27.82, 26.74, 26.72, 1.29, 1.16. calcd. for C<sub>31</sub>H<sub>56</sub>N<sub>4</sub>O<sub>5</sub>Si<sub>2</sub>Na (M + Na)<sup>+</sup>: 643.3681, found: 643.3671.


**Methyl ((S)-2-((S)-3,3-dimethyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)-3,3-dimethylbutanoyl)-L-prolinate (6d)**



The compound **6d** was prepared according to the **GP-2** with starting materials **5d**, purified by column chromatography in hexane: acetone = 4:1. **6d** was obtained as a colorless oil (19.5 mg, 37%, d.r. = 3:1), diastereomeric ratio was determined by <sup>1</sup>H NMR. <sup>1</sup>H **NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$  8.76 – 8.63 (m, 1H), 8.61 – 8.49 (m, 1H), 8.21 –

8.05 (m, 1H), 7.87 – 7.72 (m, 1H), 7.44 – 7.35 (m, 1H), 6.49 (dd,  $J = 9.2, 3.2$  Hz, 1H), 4.86 – 4.58 (m, 1H), 4.58 – 4.46 (m, 1H), 4.44 – 4.32 (m, 1H), 3.97 – 3.85 (m, 1H), 3.75 – 3.63 (m, 4H), 2.25 – 2.15 (m, 1H), 2.10 – 1.98 (m, 2H), 1.95 – 1.88 (m, 1H), 1.12 – 1.07 (m, 6H), 1.05 – 0.85 (m, 10H), 0.73 (d,  $J = 14.4$  Hz, 1H), 0.07 – -0.01 (m, 9H). **Major:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.61, 170.54, 170.02, 164.31, 149.65, 148.42, 137.39, 126.35, 122.48, 63.14, 58.94, 57.11, 52.22, 48.08, 38.14, 35.52, 29.23, 27.83, 26.79, 26.74, 26.56, 26.48, 25.26, 1.05. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.69, 170.54, 170.20, 164.19, 149.65, 148.47, 137.27, 126.29, 122.26, 63.14, 59.09, 57.17, 52.22, 48.20, 38.14, 36.23, 29.23, 27.83, 26.79, 26.74, 26.56, 26.48, 25.26, 1.05. **HRMS (ESI):** calcd. for  $\text{C}_{28}\text{H}_{45}\text{N}_3\text{O}_5\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 554.3021, found: 554.3006.


**Methyl (S)-2-((S)-3,3-dimethyl-2-((2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)pentanamido)butanamido)-3,3-dimethylbutanoate (6e)**



The compound **6e** was prepared according to the **GP-2** with starting materials **5e**, purified by column chromatography in hexane: acetone = 4:1. **6e** was obtained as a colorless oil (20.3 mg, 37%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.60 – 8.54 (m, 1H), 8.50 (d,  $J = 8.8$  Hz, 1H), 8.16 (dt,  $J = 7.6, 1.2$  Hz, 1H), 7.84 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.48 – 7.40 (m, 1H), 6.73 (d,  $J = 9.2$  Hz, 1H), 6.25 (d,  $J = 9.2$  Hz, 1H), 4.54 (dd,  $J = 8.8, 6.4$  Hz, 1H), 4.40 (d,  $J = 9.2$  Hz, 1H), 4.25 (d,  $J = 9.2$

Hz, 1H), 3.71 (s, 3H), 2.28 – 2.18 (m, 1H), 1.57 – 1.39 (m, 2H), 1.00 – 0.88 (m, 21H), 0.58 (d,  $J = 7.2$  Hz, 2H), 0.01 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.76, 171.16, 170.13, 164.53, 149.51, 148.44, 137.46, 126.50, 122.45, 61.07, 60.21, 57.79, 51.95, 37.53, 34.95, 34.84, 26.72, 26.68, 24.61, 17.33, 10.41, -0.70. **HRMS (ESI):** calcd. for  $\text{C}_{28}\text{H}_{48}\text{N}_4\text{O}_5\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 571.3286, found: 571.3261.


**Methyl ((S)-3,3-dimethyl-2-((2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)pentanamido)butanoyl)-L-valinate (6f)**



The compound **6f** was prepared according to the **GP-2** with starting materials **5f**, purified by column chromatography in hexane: acetone = 4:1. **6f** was obtained as a colorless oil (17.1 mg, 32%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.68 – 8.45 (m, 2H), 8.16 (d,  $J = 7.8$  Hz, 1H), 7.83 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.48 – 7.37 (m, 1H), 6.82 – 6.67 (m, 1H), 6.40 – 6.24 (m, 1H), 4.61 – 4.46 (m, 2H), 4.27 (dd,  $J = 9.2, 1.6$  Hz, 1H), 3.72 (s, 3H), 2.27 – 2.19 (m, 1H), 2.19 – 2.12 (m, 1H), 1.58

– 1.39 (m, 2H), 1.00 – 0.81 (m, 18H), 0.58 (d,  $J = 6.8$  Hz, 2H), 0.00 (s, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.21, 171.18, 170.33, 164.56, 149.48, 148.43, 137.47, 126.51, 122.45, 61.02, 57.83, 57.22, 52.26, 37.53, 34.82, 31.27, 26.68, 24.61, 19.13, 17.89, 17.35, 10.41, -0.72. **HRMS (ESI):** calcd. for  $\text{C}_{27}\text{H}_{46}\text{N}_4\text{O}_5\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 557.3129, found: 557.3116.

**Methyl ((S)-3,3-dimethyl-2-((S)-1-((2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)pentanoyl)-pyrrolidine-2-carboxamido)butanoyl)-L-alaninate (6g)**




The compound **6g** was prepared according to the **GP-2** with starting materials **5g**, purified by column chromatography in hexane: acetone = 4:1. **6g** was obtained as a colorless oil (23 mg, 38%). The product **6g** was partially racemic.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.62 – 8.35 (m, 2H), 8.17 – 8.08 (m, 1H), 7.88 – 7.76 (m, 1H), 7.45 – 7.36 (m, 1H), 7.30 – 7.16 (m, 1H), 6.49 – 6.31 (m, 1H), 4.95 – 4.74 (m, 1H), 4.60 – 4.45 (m, 2H), 4.22 –



4.11 (m, 1H), 4.09 – 3.86 (m, 1H), 3.79 – 3.68 (m, 4H), 2.19 – 2.10 (m, 2H), 2.02 – 1.92 (m, 3H), 1.60 – 1.45 (m, 1H), 1.38 (d,  $J = 7.2$  Hz, 3H), 1.11 – 0.81 (m, 14H), 0.77 – 0.62 (m, 1H), 0.09 – -0.06 (m, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  173.29, 172.01, 171.28, 169.92, 164.17, 149.63, 148.43, 137.32, 126.33, 122.32, 61.41, 61.23, 60.64, 54.62, 52.49, 48.17, 48.05, 38.03, 34.87, 34.60, 28.29, 26.85, 26.77, 25.36, 23.57, 18.25, 16.59, 15.53, 14.74, 9.64, -0.58. HRMS (ESI): calcd. for  $\text{C}_{30}\text{H}_{49}\text{N}_5\text{O}_6\text{SiNa}$  ( $M + \text{Na}$ ) $^+$ : 626.3344, found: 626.3329.


**Methyl ((S)-3,3-dimethyl-2-((S)-1-((2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)pentanoyl)-pyrrolidine-2-carboxamido)butanoyl)-L-valinate (6h)**



The compound **6h** was prepared according to the **GP-2** with starting materials **5h**, purified by column chromatography in hexane: acetone = 4:1. **6h** was obtained as a colorless oil (18.7 mg, 30%). The product **6h** was partially racemic.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.58 – 8.43 (m, 2H), 8.15 – 8.07 (m, 1H), 7.84 – 7.77 (m, 1H), 7.45 – 7.35 (m, 1H), 7.31 – 7.11 (m, 1H), 6.35 – 6.16 (m, 1H), 4.95 – 4.74 (m, 1H), 4.61 – 4.45 (m, 2H), 4.18 (dd,  $J = 8.6, 3.0$  Hz, 1H), 4.10 – 3.86 (m, 1H), 3.81 – 3.63 (m, 4H), 2.19 – 2.11 (m, 3H), 2.01 – 1.88 (m, 3H), 1.57 – 1.49 (m, 1H),

1.07 – 0.98 (m, 10H), 0.95 – 0.81 (m, 9H), 0.79 – 0.69 (m, 1H), 0.69 – 0.56 (m, 1H), 0.10 – -0.08 (m, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.26, 172.02, 171.29, 170.45, 164.16, 149.64, 148.43, 137.32, 126.32, 122.32, 61.57, 60.58, 57.17, 54.61, 52.20, 48.17, 38.02, 34.70, 34.39, 31.28, 28.22, 26.87, 26.79, 25.35, 23.55, 19.02, 17.89, 9.59, -0.58. HRMS (ESI): calcd. for  $\text{C}_{32}\text{H}_{53}\text{N}_5\text{O}_6\text{SiNa}$  ( $M + \text{Na}$ ) $^+$ : 654.3657, found: 654.3636.


**Methyl ((S)-3,3-dimethyl-2-((2S,3S)-2-(picolinamido)-3-((trimethylsilyl)methyl)pentanamido)butanoyl)-L-valyl-L-prolinate (6i)**



The compound **6i** was prepared according to the **GP-2** with starting materials **5i**, purified by column chromatography in hexane: acetone = 4:1. **6i** was obtained as a colorless oil (15.8 mg, 25%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.60 – 8.54 (m, 1H), 8.52 (d,  $J = 9.2$  Hz, 1H), 8.16 (dt,  $J = 7.6, 1.2$  Hz, 1H), 7.83 (td,  $J = 7.6, 1.6$  Hz, 1H), 7.47 – 7.39 (m, 1H), 6.71 (d,  $J = 9.2$  Hz, 1H), 6.49 – 6.33 (m, 1H), 4.68 – 4.42 (m, 3H), 4.24 (d,  $J = 9.2$

Hz, 1H), 3.80 – 3.64 (m, 5H), 2.28 – 2.18 (m, 2H), 2.15 – 1.96 (m, 4H), 1.53 – 1.47 (m, 1H), 1.03 – 0.84 (m, 19H), 0.65 – 0.50 (m, 2H), 0.10 – -0.05 (m, 9H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.50, 170.97, 170.28, 164.51, 149.55, 148.44, 137.42, 126.46, 122.41, 61.09, 58.89, 57.71, 55.54, 52.32, 47.34, 37.61, 34.92, 31.29, 29.14, 26.78, 25.14, 24.62, 19.54, 17.53, 17.32, 10.42, -0.70. HRMS (ESI): calcd. for  $\text{C}_{32}\text{H}_{53}\text{N}_5\text{O}_6\text{SiNa}$  ( $M + \text{Na}$ ) $^+$ : 654.3657, found: 654.3638.

**((4S, 5S, 8S, 11S, 14S)-methyl 8,11-di-tert-butyl-14-isopropyl-2,2,4-trimethyl-6,9,12-trioxo-5-(picolinamido)-7,10,13-triaza-2-silapentadecan-15-oate (6j)**




The compound **6j** was prepared according to the **GP-2** with starting materials **5j**, purified by column chromatography in hexane: acetone = 4:1. **6j** was obtained as a colorless oil (17.1 mg, 27%, d.r. = 3:1), diastereomeric ratio was determined by  $^1\text{H}$  NMR.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.69 – 8.54 (m, 2H), 8.36 – 8.27 (m, 1H), 7.89 – 7.80 (m, 1H), 7.77 – 7.50 (m,


1H), 7.46 – 7.30 (m, 2H), 6.37 – 6.16 (m, 1H), 4.87 – 4.74 (m, 1H), 4.70 – 4.55 (m, 2H), 4.47 – 4.37 (m, 1H), 3.75 (s, 3H), 2.21 – 2.05 (m, 2H), 1.00 – 0.78 (m, 28H), 0.48 – 0.26 (m, 1H), 0.00 – -0.10 (m, 9H). **Major:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.70, 171.63, 170.92, 170.63, 170.43, 164.44, 149.66, 148.44, 137.45, 126.38, 122.78, 60.99, 60.15, 59.98, 57.04, 52.21, 35.67, 34.21, 33.64, 31.18, 27.07, 26.64, 19.80, 19.68, 19.25, 17.86, -0.69. **Minor:**  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.65, 171.63, 170.92, 170.47, 170.37, 164.28, 149.68, 148.44, 137.45, 126.38, 122.74, 61.05, 60.15, 59.98, 57.08, 52.27, 35.67, 34.46, 33.23, 31.25, 27.02, 26.64, 19.80, 19.68, 19.17, 17.91, -0.62. **HRMS (ESI):** calcd. for  $\text{C}_{32}\text{H}_{55}\text{N}_5\text{O}_6\text{SiNa}$  ( $\text{M} + \text{Na}$ ) $^+$ : 656.3813, found: 656.3802.

## 5. Applications of the Alkylation Reaction


### a) Removal of the PA Group



### b) Sequential Reactions




### Methyl (S)-2-((2S,3S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((trimethylsilyl)methyl)-pentanamido)-3,3-dimethylbutanoate (**7o**)



A solution of **4o** (0.2 mmol) in THF/H<sub>2</sub>O (2:1, 3 mL) was treated with excess zinc dust (15 eq) and aqueous HCl (1.5 M, 2 mL) at room temperature and stirred for 2 hours. Then the mixture was basified by solid NaHCO<sub>3</sub>, 9-fluorenylmethyl chloroformate (3 eq) was charged into the system and the mixture was stirred overnight. The mixture was extracted with EA, the combined organic layers was washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The resulting residue was purified by column chromatography in petroleum ether: ethyl acetate:

dichloromethane = 7:1:1 to give the corresponding product **7o** as a white solid (88.9 mg, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.76 (dt, *J* = 7.6, 1.2 Hz, 2H), 7.58 (d, *J* = 7.6 Hz, 2H), 7.44 – 7.36 (m, 2H), 7.34 – 7.27 (m, 2H), 6.39 (d, *J* = 9.2 Hz, 1H), 5.35 (d, *J* = 8.8 Hz, 1H), 4.45 (d, *J* = 9.2 Hz, 1H), 4.40 (d, *J* = 7.2 Hz, 2H), 4.23 (t, *J* = 7.2 Hz, 1H), 4.16 – 4.06 (m, 1H), 3.71 (s, 3H), 2.11 – 1.96 (m, 1H), 1.52 – 1.30 (m, 2H), 1.01 – 0.82 (m, 12H), 0.54 (d, *J* = 6.8 Hz, 2H), 0.03 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.74, 171.29, 156.34, 143.99, 143.87, 141.42, 127.85, 127.22, 125.19, 120.12, 120.10, 67.25, 60.23, 59.22, 51.92, 47.27, 37.90, 34.84, 26.68, 24.57, 17.18, 10.46, -0.74. HRMS (ESI): calcd. for C<sub>31</sub>H<sub>44</sub>N<sub>2</sub>O<sub>5</sub>SiNa (M + Na)<sup>+</sup>: 575.2911, found: 575.2900.


### (S)-methyl 2-((2S,3S,4R)-4-methoxy-3-methyl-2-(picolinamido)-4-(trimethylsilyl)butanamido)-3-methylbutanoate (**8a**)



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.35 (d, *J* = 7.6 Hz, 1H), 8.67 – 8.51 (m, 1H), 8.17 (dt, *J* = 7.6, 1.2 Hz, 1H), 7.83 (td, *J* = 7.6, 1.6 Hz, 1H), 7.48 – 7.38 (m, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 4.60 (dd, *J* = 7.6, 5.2 Hz, 1H), 4.52 (dd, *J* = 8.4, 4.8 Hz, 1H), 3.70 (s, 3H), 3.47 (s, 3H), 3.38 (d, *J* = 2.0 Hz, 1H), 2.50 – 2.41 (m, 1H), 2.22 – 2.10 (m, 1H), 1.09 (d, *J* = 7.2 Hz, 3H), 0.94 – 0.88 (m, 6H), 0.12 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.17, 171.47, 165.45, 149.80, 148.63, 137.34, 126.38, 122.41, 78.37, 60.09, 59.77, 57.47, 52.19,

37.24, 31.32, 19.10, 17.99, 13.76, -1.28. HRMS (ESI): calcd. for C<sub>21</sub>H<sub>35</sub>N<sub>3</sub>O<sub>5</sub>SiNa (M + Na)<sup>+</sup>: 460.2238, found: 460.2230.

## 6. Crystal Structure of 4o







Bond precision:	C-C = 0.0064 Å		Wavelength=1.54184
Cell:	a=9.1154(3)	b=9.7854(3)	c=14.6304(5)
	alpha=90	beta=96.443(4)	gamma=90
Temperature:	293 K		
	Calculated	Reported	
Volume	1296.76(7)	1296.75(8)	
Space group	P 21	P 1 21 1	
Hall group	P 2yb	P 2yb	
Moiety formula	C22 H37 N3 O4 Si	C22 H37 N3 O4 Si	
Sum formula	C22 H37 N3 O4 Si	C22 H37 N3 O4 Si	
Mr	435.64	435.63	
Dx,g cm <sup>-3</sup>	1.116	1.116	
Z	2	2	
Mu (mm <sup>-1</sup> )	1.034	1.034	
F000	472.0	472.0	
F000'	473.81		
h,k,lmax	10,11,17	10,11,17	
Nref	4615[ 2456]	4503	
Tmin,Tmax	0.639, 0.675	0.668, 1.000	
Tmin'	0.580		
Correction method=	# Reported	T Limits:	Tmin=0.668 Tmax=1.000
AbsCorr =	MULTI-SCAN		
Data completeness=	1.83/0.98	Theta(max)= 66.895	
R(reflections)=	0.0526( 3949)	wR2(reflections)= 0.1478( 4503)	
S =	1.039	Npar= 279	



## 7. References

1. He, G.; Chen, G. A Practical Strategy for the Structural Diversification of Aliphatic Scaffolds through the Palladium-Catalyzed Picolinamide-Directed Remote Functionalization of Unactivated C(sp<sup>3</sup>)-H Bonds. *Angew. Chem., Int. Ed.* **2011**, *50*, 5192-5196.
2. He, G.; Zhao, Y.; Zhang, S.; Lu, C.; Chen, G. Highly Efficient Syntheses of Azetidines, Pyrrolidines, and Indolines via Palladium Catalyzed Intramolecular Amination of C(sp<sup>3</sup>)-H and C(sp<sup>2</sup>)-H Bonds at  $\gamma$  and  $\delta$  Positions. *J. Am. Chem. Soc.* **2012**, *134*, 3-6.
3. Zhang, L.-S.; Chen, G.; Wang, X.; Guo, Q.-Y.; Zhang, X.-S.; Pan, F.; Chen, K.; Shi, Z.-J. Direct Borylation of Primary C-H Bonds in Functionalized Molecules by Palladium Catalysis. *Angew. Chem., Int. Ed.* **2014**, *53*, 3899-3903.
4. Zhang, S.-Y.; He, G.; Zhao, Y.; Wright, K.; Nack, W. A.; Chen, G. Efficient Alkyl Ether Synthesis via Palladium-Catalyzed, Picolinamide-Directed Alkoxylation of Unactivated C(sp<sup>3</sup>)-H and C(sp<sup>2</sup>)-H Bonds at Remote Positions. *J. Am. Chem. Soc.* **2012**, *134*, 7313-7216.
5. Zhang, S.-Y.; He, G.; Nack, W. A.; Zhao, Y.; Li, Q.; Chen, G. Palladium-Catalyzed Picolinamide-Directed Alkylation of Unactivated C(sp<sup>3</sup>)-H Bonds with Alkyl Iodides. *J. Am. Chem. Soc.* **2013**, *135*, 2124-2127.
6. Fan, M.; Ma, D.-W. Palladium-Catalyzed Direct Functionalization of 2-Aminobutanoic Acid Derivatives: Application of a Convenient and Versatile Auxiliary. *Angew. Chem., Int. Ed.* **2013**, *52*, 12152-12155.
7. Rodriguez, N.; Romero-Revilla, J. A.; Fernandez-Ibanez, M. A.; Carretero, J. C. Palladium-catalyzed *N*-(2-pyridyl)sulfonyl-directed C(sp<sup>3</sup>)-H  $\gamma$ -arylation of Amino Acid Derivatives. *Chem. Sci.* **2013**, *4*, 175-179.
8. Xu, J.-W.; Zhang, Z.-Z.; Rao, W.-H.; Shi, B.-F. Site-Selective Alkenylation of  $\delta$ -C(sp<sup>3</sup>)-H Bonds with Alkynes via a Six-Membered Palladacycle. *J. Am. Chem. Soc.* **2016**, *138*, 10750-11753.
9. Zhan, B.-B.; Li, Y.; Xu, J.-W.; Nie, X.-L.; Fan, J.; Jin, L.; Shi, B.-F. Site-Selective  $\delta$ -C(sp<sup>3</sup>)-H Alkylation of Amino Acids and Peptides with Maleimides via a Six-Membered Palladacycle. *Angew. Chem. Int. Ed.* **2018**, *57*, 5858-5862.



## 8. NMR Spectra


















































































































































































































































































































































## 9. Copies of HPLC analysis

1a: AD-H, Hex/*i*PrOH = 90/10, rate = 1.0 mL/min, 254 nm

<色谱图>

mV




<峰表>

检测器A 254nm

峰号	保留时间	面积	高度	浓度	浓度单位	标记	化合物名
1	9.612	3058710	205780	50.164		M	
2	11.985	3038730	162915	49.836			
总计		6097440	368695				

<色谱图>

mV



<峰表>


检测器A 254nm

峰号	保留时间	面积	高度	浓度	浓度单位	标记	化合物名
1	9.555	168522	14251	0.897		M	
2	11.965	18622977	980220	99.103		M	
总计		18791498	994471				

**2a: IB-N5, Hex/iPrOH = 97/3, rate = 0.8 mL/min, 254 nm**

<色谱图>

mV




<峰表>

检测器A 254nm

峰号	保留时间	面积	高度	浓度	浓度单位	标记	化合物名
1	15.077	2327032	111312	11.500		M	
2	16.394	8293999	309752	40.990		M	
3	17.760	2051967	77857	10.141			
4	20.992	7561197	200200	37.368		S	
总计		20234195	699121				

<色谱图>

mV



<峰表>

检测器A 254nm

峰号	保留时间	面积	高度	浓度	浓度单位	标记	化合物名
1	14.871	4741003	224983	18.490		M	
2	16.062	20779405	673470	81.040		M	
3	21.174	120636	2195	0.470		M	
总计		25641043	900648				